<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Taxanes for adjuvant treatment of early breast cancer - Willson, ML - 2019 | Cochrane Library</title> <meta content="Taxanes for adjuvant treatment of early breast cancer - Willson, ML - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004421.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Taxanes for adjuvant treatment of early breast cancer - Willson, ML - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004421.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004421.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Taxanes for adjuvant treatment of early breast cancer" name="citation_title"/> <meta content="Melina L Willson&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="NHMRC Clinical Trials Centre, The University of Sydney" name="citation_author_institution"/> <meta content="Lucinda Burke&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Chris O'Brien Lifehouse" name="citation_author_institution"/> <meta content="Thomas Ferguson" name="citation_author"/> <meta content="Royal Perth Hospital" name="citation_author_institution"/> <meta content="Davina Ghersi" name="citation_author"/> <meta content="Anna K Nowak" name="citation_author"/> <meta content="Sir Charles Gairdiner Hospital and University of Western Australia" name="citation_author_institution"/> <meta content="Nicholas Wilcken" name="citation_author"/> <meta content="nicholas.wilcken@sydney.edu.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD004421.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/09/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004421.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004421.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004421.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents, Phytogenic [*therapeutic use]; Breast Neoplasms [*drug therapy]; Chemotherapy, Adjuvant; Neoadjuvant Therapy; Paclitaxel [therapeutic use]; Randomized Controlled Trials as Topic; Taxoids [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004421.pub3&amp;doi=10.1002/14651858.CD004421.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="uYcNEb5O";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004421\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004421\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","zh_HANS","ja","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004421.pub3",title:"Taxanes for adjuvant treatment of early breast cancer",firstPublishedDate:"Sep 2, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Breast Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004421.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004421.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004421.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004421.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004421.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004421.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004421.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004421.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004421.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004421.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7940 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004421.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-sec1-0006"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/appendices#CD004421-sec1-0012"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/table_n/CD004421StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/table_n/CD004421StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Taxanes for adjuvant treatment of early breast cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/information#CD004421-cr-0002">Melina L Willson</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/information#CD004421-cr-0003">Lucinda Burke</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/information#CD004421-cr-0004">Thomas Ferguson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/information#CD004421-cr-0005">Davina Ghersi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/information#CD004421-cr-0006">Anna K Nowak</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004421.pub3/information#CD004421-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Nicholas Wilcken</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/information/en#CD004421-sec1-0016">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 September 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004421.pub3">https://doi.org/10.1002/14651858.CD004421.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004421-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004421-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004421-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004421-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004421-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004421-abs-0001" lang="en"> <section id="CD004421-abs1-0001"> <h3 class="title" id="CD004421-abs1-0001">Background</h3> <p>Adjuvant chemotherapy improves survival in premenopausal and postmenopausal women with early breast cancer. Taxanes are highly active chemotherapy agents used in metastatic breast cancer. Review authors examined their role in early breast cancer. This review is an update of a Cochrane Review first published in 2007. </p> </section> <section id="CD004421-abs1-0002"> <h3 class="title" id="CD004421-abs1-0002">Objectives</h3> <p>To assess the effects of taxane‐containing adjuvant chemotherapy regimens for treatment of women with operable early breast cancer. </p> </section> <section id="CD004421-abs1-0003"> <h3 class="title" id="CD004421-abs1-0003">Search methods</h3> <p>For this review update, we searched the Specialised Register of the Cochrane Breast Cancer Group, MEDLINE, Embase, CENTRAL (2018, Issue 6), the WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov on 16 July 2018, using key words such as 'early breast cancer' and 'taxanes'. We screened reference lists of other related literature reviews and articles, contacted trial authors, and applied no language restrictions. </p> </section> <section id="CD004421-abs1-0004"> <h3 class="title" id="CD004421-abs1-0004">Selection criteria</h3> <p>Randomised trials comparing taxane‐containing regimens versus non‐taxane‐containing regimens in women with operable breast cancer were included. Studies of women receiving neoadjuvant chemotherapy were excluded. </p> </section> <section id="CD004421-abs1-0005"> <h3 class="title" id="CD004421-abs1-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed risk of bias and quality of the evidence using the GRADE approach. Hazard ratios (HRs) were derived for time‐to‐event outcomes, and meta‐analysis was performed using a fixed‐effect model. The primary outcome measure was overall survival (OS); disease‐free survival (DFS) was a secondary outcome measure. Toxicity was represented as odds ratios (ORs), and quality of life (QoL) data were extracted when present. </p> </section> <section id="CD004421-abs1-0006"> <h3 class="title" id="CD004421-abs1-0006">Main results</h3> <p>This review included 29 studies (27 full‐text publications and 2 abstracts or online theses). The updated analysis included 41,911 randomised women; the original review included 21,191 women. Taxane‐containing regimens improved OS (HR 0.87, 95% confidence interval (CI) 0.83 to 0.92; high‐certainty evidence; 27 studies; 39,180 women; 6501 deaths) and DFS (HR, 0.88, 95% CI 0.85 to 0.92; high‐certainty evidence; 29 studies; 41,909 women; 10,271 reported events) compared to chemotherapy without a taxane. There was moderate to substantial heterogeneity across studies for OS and DFS (respectively). </p> <p>When a taxane‐containing regimen was compared with the same regimen without a taxane, the beneficial effects of taxanes persisted for OS (HR 0.84, 95% CI 0.77 to 0.92; P &lt; 0.001; 7 studies; 10,842 women) and for DFS (HR 0.84, 95% CI 0.78 to 0.90; P &lt; 0.001; 7 studies; 10,842 women). When a taxane‐containing regimen was compared with the same regimen with another drug or drugs that were substituted for the taxane, a beneficial effect was observed for OS and DFS with the taxane‐containing regimen (OS: HR 0.80, 95% CI 0.74 to 0.86; P &lt; 0.001; 13 studies; 16,196 women; DFS: HR 0.83, 95% CI 0.78 to 0.88; P &lt; 0.001; 14 studies; 16,823 women). Preliminary subgroup analysis by lymph node status showed a survival benefit with taxane‐containing regimens in studies of women with lymph node‐positive disease only (HR 0.83, 95% CI 0.78 to 0.88; P &lt; 0.001; 17 studies; 22,055 women) but less benefit in studies of women both with and without lymph node metastases or with no lymph node metastases. Taxane‐containing regimens also improved DFS in women with lymph node‐positive disease (HR 0.84, 95% CI 0.80 to 0.88; P &lt; 0.001; 17 studies; 22,055 women), although the benefit was marginal in studies of women both with and without lymph node‐positive disease (HR 0.95, 95% CI 0.88 to 1.02; 9 studies; 12,998 women) and was not apparent in studies of women with lymph node‐negative disease (HR 0.99, 95% CI 0.86 to 1.14; 3 studies; 6856 women). </p> <p>Taxanes probably result in a small increase in risk of febrile neutropenia (odds ratio (OR) 1.55, 95% CI 0.96 to 2.49; moderate‐certainty evidence; 24 studies; 33,763 women) and likely lead to a large increase in grade 3/4 neuropathy (OR 6.89, 95% CI 3.23 to 14.71; P &lt; 0.001; moderate‐certainty evidence; 22 studies; 31,033 women). Taxanes probably cause little or no difference in cardiotoxicity compared to regimens without a taxane (OR 0.87, 95% CI 0.56 to 1.33; moderate‐certainty evidence; 23 studies; 32,894 women). Seven studies reported low‐quality evidence for QoL; overall, taxanes may make little or no difference in QoL compared to chemotherapy without a taxane during the follow‐up period; however, the duration of follow‐up differed across studies. Only one study, which was conducted in Europe, provided cost‐effectiveness data. </p> </section> <section id="CD004421-abs1-0007"> <h3 class="title" id="CD004421-abs1-0007">Authors' conclusions</h3> <p>This review of studies supports the use of taxane‐containing adjuvant chemotherapy regimens, with improvement in overall survival and disease‐free survival for women with operable early breast cancer. This benefit persisted when analyses strictly compared a taxane‐containing regimen versus the same regimen without a taxane or the same regimen with another drug that was substituted for the taxane. Preliminary evidence suggests that taxanes are more effective for women with lymph node‐positive disease than for those with lymph node‐negative disease. Considerable heterogeneity across studies probably reflects the varying efficacy of the chemotherapy backbones of the comparator regimens used in these studies. This review update reports results that are remarkably consistent with those of the original review, and it is highly unlikely that this review will be updated, as new trials are assessing treatments based on more detailed breast cancer biology. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004421-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004421-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004421-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004421-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD004421-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004421-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004421-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004421-abs-0005" lang="en"> <h3>Taxane‐containing chemotherapy for women after surgery for early breast cancer</h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this Cochrane Review was to find out if adding taxane drugs to standard chemotherapy improves survival and is safe for women with early breast cancer. Cochrane Review authors collected and analysed all relevant studies to answer these questions and found 29 studies. </p> <p><b>Key messages</b> </p> <p>Adding a taxane drug to standard chemotherapy improved survival (women lived longer) and reduced the chance of cancer returning in women with operable early breast cancer, but the use of taxanes probably led to increased risk of some side effects such as febrile neutropenia (low white cell count with fever) and neuropathy (damage to the nerves). </p> <p><b>What was studied in this review?</b> </p> <p>Early breast cancer is cancer that has not spread beyond the breast or nearby lymph nodes. It may be curable with surgery alone, but there is a risk that after surgery the breast cancer may return. Chemotherapy and radiotherapy are needed after surgery to achieve a cure. </p> <p>A combination of chemotherapy drugs, rather than one drug by itself, is usually used to treat early breast cancer. </p> <p>One class of chemotherapy drugs commonly used is taxanes. Taxanes act by stalling the cellular processes that are needed for cells to divide. This action causes cancer cells to stop dividing and slows the growth of cancer or kills the cells. Two main taxane drugs are available ‐ paclitaxel and docetaxel. </p> <p>The practice of adding taxanes to standard chemotherapy has increased over the last 10 years as data from clinical trials have become available. There is a need to review these data to find out the benefits of these drugs, any side effects of the drugs, and how treatment is affecting a woman's overall well‐being (quality of life). </p> <p><b>What are the main results of this review?</b> </p> <p>Review authors found 29 relevant studies involving 41,911 women. These studies compared chemotherapy that contained a taxane against chemotherapy that did not contain a taxane. Around half of the studies used paclitaxel, and the other half used docetaxel. The decision whether to use paclitaxel or docetaxel generally was based on the availability of these drugs in the hospital. Researchers gave these drugs by injection into a vein. </p> <p>The women's health was monitored for at least 12 months from the start of the study. Some studies monitored women for 10 years. </p> <p>Review authors found that adding a taxane drug to chemotherapy:</p> <p>• improves survival and reduces the risk of cancer coming back compared to chemotherapy with no taxane; </p> <p>• probably leads to an increased chance of some side effects compared to chemotherapy with no taxane. Side effects that are more likely to occur due to taxanes are febrile neutropenia (low white cell count with fever) and neuropathy (damage to the nerves); </p> <p>• probably makes little or no difference in heart function compared to chemotherapy with no taxane; and </p> <p>• may make little or no difference in quality of life for women compared to chemotherapy with no taxane. Seven of 29 studies provided information on the quality of life of women. </p> <p>Very little information is available on the costs of adding a taxane to chemotherapy; only one study, which was conducted in Europe, reported cost‐effectiveness data. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The review authors searched for studies that had been published up to July 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004421-sec1-0007" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004421-sec1-0007">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004421-sec1-0024">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004421-sec1-0007"></div> <h3 class="title" id="CD004421-sec1-0008">Implications for practice</h3> <section id="CD004421-sec1-0008"> <p>High‐certainty evidence supports the conclusion that use of a taxane drug as part of the adjuvant chemotherapy regimen following surgery for early‐stage breast cancer improves both overall survival and disease‐free survival in women with moderate to high risk of recurrence. Despite considerable heterogeneity across studies, taxane‐containing regimens provided benefit for survival and disease‐free survival compared to non‐taxane‐containing chemotherapy. A taxane‐containing regimen should be considered for women in this situation following assessment of individual risk of recurrence and comorbidities. Additional toxicity is associated with use of a taxane‐containing regimen. Toxicity implications should be discussed with individual women who are considering taxane‐based adjuvant chemotherapy regimens. Review authors found a paucity of studies examining effects of taxane‐containing chemotherapy on patient‐reported quality of life. </p> </section> <h3 class="title" id="CD004421-sec1-0009">Implications for research</h3> <section id="CD004421-sec1-0009"> <p>A next generation of studies is required to further define the precise role of taxanes as adjuvant chemotherapy for early breast cancer. Future randomised trials comparing docetaxel with paclitaxel; addressing questions of dose density, scheduling, and duration; and looking at how best to combine taxane and anthracycline‐based treatment, and how to combine taxanes with trastuzumab in women with HER2‐positive disease will help to answer these questions. In many of the studies included in this review version, tumour profiling was not conducted at the time this review commenced. As this review update reported results that were remarkably consistent with those presented in the original review, even with the addition of over 20,000 women, it is highly unlikely that future studies will change the key findings; therefore we do not plan to update this review in the future. Instead, a new review topic would be warranted to assess taxane treatment based on detailed knowledge of the breast cancer subtype and to collect data related to toxicities and quality of life over the long term. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004421-sec1-0001" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004421-sec1-0001"></div> <div class="table" id="CD004421-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Taxane‐containing chemotherapy vs any chemotherapy without taxane for early breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Taxane‐containing chemotherapy compared to any chemotherapy without taxane for early breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with early breast cancer (operable, stages I to IIIA)<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> taxane‐containing chemotherapy<br/> <b>Comparison:</b> any chemotherapy without taxanes </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any chemotherapy without taxanes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with taxane‐containing chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Overall survival<br/> Follow‐up: range 5 years to 10 years<br/> <br/> (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk of death</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.87<br/> (0.83 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>39,180<br/> (27 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Additional analyses (including specific taxane, scheduling, treatment duration, doses, node positive, and risk of bias) showed equivalent efficacy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000*</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b><br/> (67 to 73) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High risk of death</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000*</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b><br/> (169 to 184) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Disease‐free progression<br/> Follow‐up: range 4 years to 10 years<br/> <br/> (*baseline risks for low‐ and high‐risk groups in the control arm were estimated at 5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk of recurrence</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.88<br/> (0.85 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>41,909<br/> (29 studies, 30 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>As above for overall survival</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 per 1000*</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b><br/> (120 to 130) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High risk of recurrence</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000*</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b><br/> (280 to 299) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> Follow‐up: 1 to 62 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not estimable. In general, there did not seem to be differences in quality of life scores between groups at long‐term follow‐up </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(7 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies used the validated EORTC‐C30 questionnaire and measures were patient‐reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Febrile neutropenia<br/> Follow‐up: 3 to 7 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.43<br/> (0.89 to 2.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34,154<br/> (23 studies, 24 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There was a higher incidence of febrile neutropenia with docetaxel‐containing regimens</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b><br/> (50 to 120) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neuropathy (including grade 3/4 sensory or motor neuropathy, or both)<br/> Follow‐up: 3 to 7 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 6.89 (3.23 to 14.71)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31,033<br/> (22 studies, 23 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A test for subgroup differences by taxane type was not significant</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1,000</b><br/> (18 to 76) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiotoxicity (including grade 3/4 and congestive cardiac failure)<br/> Follow‐up: 3 to 10 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.87<br/> (0.56 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>32,894<br/> (23 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of cardiotoxicity was reduced with lower planned dose of anthracycline</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/> (5 to 12) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; HR: hazard ratio; OR: odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Heterogeneity was detected (I² = 59%) mainly due to variations in chemotherapy backbones. The quality of evidence was not downgraded as variations in chemotherapy are likely to occur in clinical practice.<br/> <sup>b</sup>This outcome was downgraded because all measures were patient‐reported, taking place in open‐label studies, and therefore at high risk of bias. Although all studies used the validated EORTC‐C30 questionnaires, the time frames when women were given the questionnaires was variable, and lengths of follow‐up were different. In one study, only 23% of participants completed baseline and end of chemotherapy questionnaires.<br/> <sup>c</sup>There was significant heterogeneity across studies (I² = 96% for febrile neutropenia; I² = 82% for neuropathy).<br/> <sup>d</sup>The confidence interval crosses the line of no effect and does not rule out a small increase in toxicity from taxanes. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004421-sec1-0002" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004421-sec1-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004421-sec1-0020">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD004421-sec1-0002"></div> <section id="CD004421-sec2-0001"> <h3 class="title" id="CD004421-sec2-0001">Description of the condition</h3> <p>Breast cancer is a major cause of morbidity and mortality among women worldwide. In 2012, an estimated 1.67 million new cases and over 522,000 deaths occurred (<a href="./references#CD004421-bbs2-0058" title="FerlayJ , SoerjomataramI , DikshitR , EserS , MathersC , RebeloM , et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer2015;136:E359‐86. ">Ferlay 2015</a>). Depending on the stage of early breast cancer, five‐year relative survival rates can range from 90% (stage II) to almost 100% (stage 0 or stage I) (<a href="./references#CD004421-bbs2-0052" title="Breast cancer in Australia: an overview. Australian Institute of Health and Welfare &amp; Cancer Australia. Case series no. 71. Canberra: Cat no CAN 67,October 2012. ">AIHW 2012</a>). </p> <p>The primary treatment for early breast cancer is local, and surgery with or without radiotherapy is recommended for women with operable early breast cancer (<a href="./references#CD004421-bbs2-0063" title="National Comprehensive Cancer Network Practice Guidelines in Oncology: Breast Cancer; Version 2, 2007. www.nccn.org/professionals/physician_gls/PDF/breast.pdf (accessed 30 April 2007). ">NCCN 2007</a>). Adjuvant polychemotherapy following surgery improves survival among premenopausal and postmenopausal women with early breast cancer (<a href="./references#CD004421-bbs2-0057" title="Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15‐year survival: an overview of the randomised trials.. Lancet2005;365:1687‐1717. ">EBCTCG 2005</a>). </p> </section> <section id="CD004421-sec2-0002"> <h3 class="title" id="CD004421-sec2-0002">Description of the intervention</h3> <p>Two taxanes are commercially available: paclitaxel (Taxol®, Bristol‐Myers Squibb) and docetaxel (Taxotere®, Sanofi‐Aventis). Extensive research has led to the creation of new second‐generation taxanes and additional non‐taxane microtubule‐targeting chemotherapies. Currently two new taxanes have been approved by the FDA: nab paclitaxel (Abraxane®, Celgene), which was approved in 2005 for treatment of refractory, relapsed, or metastatic breast cancer; and cabazitaxel (Jevtana®, Sanofi), which was approved in 2010 for use in hormone‐refractory metastatic prostate cancer. Additionally, two non‐taxane microtubule‐targeting agents have received FDA approval for use in breast cancer: ixabepilone (Ixempra®, Bristol‐Myers Squibb) in 2007, and eribulin (Halaven®, Eisai Co., Ltd.) in 2010. </p> <p>The most common side effects differ slightly between the two available taxanes. Both agents cause neutropenia (low neutrophil count, a subset of white blood cells) and thrombocytopenia (low platelet count), as well as fatigue, nausea and vomiting, hair loss, diarrhoea, mouth ulcers, and joint and muscle pain. Paclitaxel also causes hypersensitivity reactions (skin rash and reactions to infusion of the agent) and peripheral neuropathy. Docetaxel also causes skin and nail changes and fluid accumulation (oedema). Both drugs can cause febrile neutropenia (serious infection due to low neutrophil count), which occasionally can be life‐threatening or fatal. Supportive therapies can modify many of these side effects. </p> </section> <section id="CD004421-sec2-0003"> <h3 class="title" id="CD004421-sec2-0003">How the intervention might work</h3> <p>Taxanes are cytotoxic chemotherapy agents that affect cellular structures needed for cancer cells to divide ‐ the microtubules. In a normal cell cycle, cells form microtubules at the beginning of cell division, and the microtubules are broken down when the cell stops dividing. Taxanes stabilise the microtubules, preventing them from breaking down normally. This causes the cancer cells to stop dividing, potentially slowing the growth of cancer or killing the cells. </p> </section> <section id="CD004421-sec2-0004"> <h3 class="title" id="CD004421-sec2-0004">Why it is important to do this review</h3> <p>Taxanes are among the most active agents in metastatic breast cancer (<a href="./references#CD004421-bbs2-0053" title="BishopJF , DewarJ , TonerGC , SmithJ , TattersallMH , OlverIN , et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front‐line therapy in untreated metastatic breast cancer. Journal of Clinical Oncology1999;17(8):2355‐64. ">Bishop 1999</a>; <a href="./references#CD004421-bbs2-0055" title="ChanS , FriedrichsK , NoelD , PinterT , VanBelleS , VorobiofD , et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. Journal of Clinical Oncology1999;17(8):2341‐54. [MEDLINE: 20030025] ">Chan 1999</a>; <a href="./references#CD004421-bbs2-0059" title="GhersiD , WilckenN , SimesJ , DonoghueE . Taxane containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD003366] ">Ghersi 2005</a>); they are widely used (<a href="./references#CD004421-bbs2-0056" title="CrownJ , DierasV , KaufmannM , vonMinckwitzG , KayeS , LeonardR , et al. Chemotherapy for metastatic breast cancer ‐ report of a European expert panel. Lancet Oncology2002;3(12):719‐27. [MEDLINE: 22361949] ">Crown 2002</a>). Their incorporation into adjuvant regimens for early breast cancer has increased in recent years as mature data from clinical trials have become available. For this review update, data on an additional 19,416 participants were available, with time‐to‐event data provided for most of the randomised participants. Other systematic reviews have examined this topic: <a href="./references#CD004421-bbs2-0054" title="BriaE , NisticoC , CupponeF , CarliniP , CiccareseM , MilellaM , et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer2006;106(11):2337‐44. ">Bria 2006</a> and <a href="./references#CD004421-bbs2-0065" title="QinYY , LiH , GuoKJ , YeXF , WeiX , ZhouYH , et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta‐analysis of 19 randomized trials with 30698 patients. PLoS ONE2011;6(11):e26946. ">Qin 2011</a>; however, these reviews did not include risk of bias assessments for the included studies as per Cochrane's risk of bias tool and did not grade the overall quality of evidence for each main outcome. An update of the efficacy and safety of taxanes in the form of an updated Cochrane Review seems warranted given the availability of mature follow‐up data and new trial data. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004421-sec1-0003" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004421-sec1-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004421-sec1-0021">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004421-sec1-0003"></div> <p>To assess the effects of taxane‐containing adjuvant chemotherapy regimens for treatment of women with operable early breast cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004421-sec1-0004" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004421-sec1-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004421-sec1-0022">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004421-sec1-0004"></div> <section id="CD004421-sec2-0005"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004421-sec3-0001"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials are included. Quasi‐randomised trials were excluded.</p> <p>We included studies with full‐text publications and studies published in abstract form only. We excluded studies available only as protocols and those published without the outcome measures of interest in this review. </p> </section> <section id="CD004421-sec3-0002"> <h4 class="title">Types of participants</h4> <p>We included women of any age with histologically confirmed operable breast cancer (stages I to IIIA). </p> <p>We excluded women who received neoadjuvant chemotherapy. We included studies that included both women who received adjuvant chemotherapy and women who received neoadjuvant chemotherapy if data for the two groups were reported separately. </p> </section> <section id="CD004421-sec3-0003"> <h4 class="title">Types of interventions</h4> <p>We defined an intervention as any chemotherapy regimen that contains a taxane.<br/> We defined a comparator as any chemotherapy regimen that does not contain a taxane. </p> <p>Comparisons included the following.</p> <p> <ul id="CD004421-lst1-0001"> <li> <p>Question 1. Taxane‐containing regimen versus the same regimen without a taxane.</p> </li> <li> <p>Question 2. Any taxane‐containing regimen versus any regimen without a taxane.</p> </li> <li> <p>Question 3. Any taxane‐containing regimen versus the same regimen with another drug or drugs that were substituted for the taxane. </p> </li> </ul> </p> <p>Endocrine treatment and targeted therapy were allowed if the same treatment was given to all groups. </p> <p>The taxane drugs used were paclitaxel and docetaxel.</p> </section> <section id="CD004421-sec3-0004"> <h4 class="title">Types of outcome measures</h4> <section id="CD004421-sec4-0001"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD004421-lst1-0002"> <li> <p>Overall survival (OS), defined as time from randomisation/study entry until death from any cause </p> </li> </ul> </p> </section> <section id="CD004421-sec4-0002"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD004421-lst1-0003"> <li> <p>Disease‐free survival (DFS), defined as time from date of randomisation to first date of a local, regional, or distant relapse, diagnosis of a second primary cancer, or death from any cause </p> </li> <li> <p>Toxicity, defined by World Health Organization (WHO)/National Cancer Institute of Canada (NCIC) toxicity criteria </p> </li> <li> <p>Quality of life (QoL), assessed by validated or trial‐specific instruments such as the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire </p> </li> <li> <p>Cost‐effectiveness</p> </li> </ul> </p> </section> </section> </section> <section id="CD004421-sec2-0006"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004421-sec3-0005"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases on 16 July 2018.</p> <p> <ul id="CD004421-lst1-0004"> <li> <p>Specialised Register of the Cochrane Breast Cancer Group. Details of the search strategy used by the Group for identification of studies and the procedure used to code references are outlined in the Group's module (<a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html" target="_blank">www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html</a>). Studies coded as 'early breast cancer' and 'chemotherapy' on the Specialised Register were extracted and combined with the keywords 'taxol', 'docetaxel', and 'paclitaxel'. A search was carried out for the following text words: 'taxane', 'taxol', 'taxotere', 'paclitaxel', 'paxene', 'nsc‐12973', 'docetaxel', 'anzatax', 'taxanes', 'taxoids', and 'taxoid'. </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 6) (see <a href="./appendices#CD004421-sec2-0016">Appendix 1</a>). </p> </li> <li> <p>MEDLINE (via OvidSP) (see <a href="./appendices#CD004421-sec2-0017">Appendix 2</a>). </p> </li> <li> <p>Embase (via Embase.com) (see <a href="./appendices#CD004421-sec2-0018">Appendix 3</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal for all prospectively registered and ongoing trials (see <a href="./appendices#CD004421-sec2-0019">Appendix 4</a>). </p> </li> <li> <p>ClinicalTrials.gov register (clinicaltrials.gov) for additional unpublished and ongoing studies (see <a href="./appendices#CD004421-sec2-0020">Appendix 5</a>). </p> </li> </ul> </p> </section> <section id="CD004421-sec3-0006"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of other related literature reviews and articles.</p> <p>We performed handsearching for abstracts published from 1995 to 2006 for presentations at the American Society of Clinical Oncology Annual Scientific Meeting, and up until 2009 for the San Antonio Breast Cancer Symposium. </p> </section> </section> <section id="CD004421-sec2-0007"> <h3 class="title" id="CD004421-sec2-0007">Data collection and analysis</h3> <section id="CD004421-sec3-0007"> <h4 class="title">Selection of studies</h4> <p>In the original review and review update, two review authors (original review: AN, TF; review update: MW, LB) applied the selection criteria to each trial publication (if full publication available) or abstract (full publication not available). A third review author was available to resolve any disagreements regarding eligibility (review update: NW). </p> <p>We have recorded excluded studies in the <a href="./references#CD004421-sec2-0024" title="">Characteristics of excluded studies</a> table. </p> <p>We applied no language restrictions.</p> </section> <section id="CD004421-sec3-0008"> <h4 class="title">Data extraction and management</h4> <p>For the original review and review update, two review authors (original review: AN, TF; review update: MW, LB) independently extracted data from the included studies. If required, a third review author (NW) was available to resolve any discrepancies regarding extraction of quantitative data. We collected information on study design, participants (including hormone receptor status and nodal involvement), settings, interventions, primary and secondary outcomes, follow‐up, and sources of funding. For studies with more than one publication, we extracted data from these publications, and we considered the final or updated version of each study as the primary reference. </p> </section> <section id="CD004421-sec3-0009"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For the review update, we used Cochrane's 'Risk of bias' assessment tool to assess potential sources of bias in the included studies (<a href="./references#CD004421-bbs2-0061" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Two review authors (MW, LB) independently assessed the potential risk of bias for each study and resolved any differences in judgement through discussion. The domains assessed were random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. We assigned ratings of 'high', 'low', or 'unclear' risk of bias to each domain for each included study in keeping with the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004421-bbs2-0061" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Among phase III oncology studies, open‐label studies are common due to the difficulty involved in concealing different chemotherapy schedules and toxicities. The blinding of outcome assessment domain was therefore grouped with outcome measures most unlikely or most likely to be influenced by lack of blinding. Outcomes were segregated into (1) overall survival, (2) disease‐free survival and toxicity, and (3) quality of life. </p> </section> <section id="CD004421-sec3-0010"> <h4 class="title">Measures of treatment effect</h4> <p>The primary outcome for this review was overall survival, and the secondary outcome was disease‐free survival, with both considered as time‐to‐event outcomes. Hazard ratios (HRs) and variances were extracted from trial publications, when available. If not reported, statistics were extracted from publications via the methods described by Parmar et al using other summary statistics, or from data from published Kaplan‐Meier curves in the original review (<a href="./references#CD004421-bbs2-0064" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. [MEDLINE: 99120172] ">Parmar 1998</a>). Numbers at risk were adjusted based on estimated minimum and maximum follow‐up times. When these were not reported, minimum follow‐up was estimated from parameters given, including date of final accrual, date of study closure, date of submission, and estimated time to complete treatment. Maximum follow‐up time was similarly estimated from date of first accrual, date of analysis, date of submission, and last event on the time‐to‐event curve. For the review update, if required, we calculated summary statistics indirectly using the methods outlined by Tierney (<a href="./references#CD004421-bbs2-0068" title="TierneyJ , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Methodology2007;8:16. ">Tierney 2007</a>; indirect methods were recorded in the Notes section in the <a href="./references#CD004421-sec2-0023" title="">Characteristics of included studies</a> tables). All efficacy analyses used an intention‐to‐treat population when this was reported. A pooled HR was calculated using observed (O) minus expected (E) event numbers, and variance from each trial was derived as above in a fixed‐effect model (<a href="./references#CD004421-bbs2-0069" title="YusufS , WittesJ , ProbstfieldJ , TyrolerHA . Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA1991;266(1):93‐8. ">Yusuf 1991</a>). </p> <p>The treatment effect was also analysed by subgroups for hormone receptor status. In this case, HRs and confidence intervals (CIs) reported in hormone receptor‐positive women and hormone receptor‐negative women were analysed, when available. </p> <p>For two studies (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>), missing data were estimated using the formula HR = [(taxane events)/(taxane participants)]/[(control events)/(control participants)]. For <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>, this formula was used to estimate the number of participants per treatment group, and for <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>, the formula was used to estimate the number of events per treatment group for overall survival and for disease‐free survival. </p> <p>Toxicity data were extracted from each trial by one or two review authors (original review: RV; review update: MW, LB); when possible, this was done for the treated population rather than the intention‐to‐treat population. As definitions of toxic events varied between trials, events were extracted and summarised to best reflect clinically important outcomes. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each toxicity via a random‐effects model, when that toxicity was reported in four or more trials. For this review, toxicity was abstracted only from the primary publication used to report efficacy or from a publication solely on toxicity, even when other published abstracts had reported separately on toxicity. </p> <p>Quality of life (QoL) data were collected using the EORTC Common Toxicity Criteria (CTC) questionnaire, and four of the six trials reported data in a full publication. No attempt was made to statistically synthesise QoL data, which are summarised and reported qualitatively. </p> <p>Pharmacoeconomic data were reported for only one trial, and a description was provided in the <a href="./full#CD004421-sec1-0005">Results</a> section. </p> </section> <section id="CD004421-sec3-0011"> <h4 class="title">Unit of analysis issues</h4> <p>Three trials were three‐arm studies (<a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>). For <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>, data from two of the three arms were used for this review (the third being a neoadjuvant treatment arm). For NCIC CTG MA21, the control group was halved to allow a comparison with each of the two taxane arms (<a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a>; <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>). For <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>, the two control arms (epirubicin (e)‐cyclophosphamide, methotrexate, and fluorouracil (CMF) and fluorouracil/epirubicin/cyclophosphamide (FEC)) were combined. </p> <p>Two trials were four‐arm studies (<a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>). For <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>, the two control arms were combined, as were the two taxane arms. However, for the analysis related to sequential versus concurrent anthracycline/taxane, data comparing uncombined study arms were used (concurrent control vs concurrent taxane, and sequential control vs sequential taxane). For <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>, the two control arms (4‐ and 6‐cycle regimens) were combined, and the two taxane arms (four‐ and six‐cycle regimens) were combined. </p> </section> <section id="CD004421-sec3-0012"> <h4 class="title">Dealing with missing data</h4> <p>When data were missing, we contacted the original investigators (by written correspondence) to request missing data. For the review update, we contacted the following trialists for summary statistics, numbers of events for each treatment arm (for overall survival or disease‐free survival), and clarification on whether HRs were adjusted or unadjusted: <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0046" title="KaderYA , El‐NahasT , SakrA . Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens. OncoTargets and Therapy2013;6:1073‐7. ">Kader</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>. We received additional data from the trialists for seven studies: <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>. </p> </section> <section id="CD004421-sec3-0013"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was assessed by using the Chi² test and the I² statistic, as well as visual inspection of forest plots. The graphical representation of data was inspected; if confidence intervals for the results of individual studies had poor overlap, this generally indicated the presence of statistical heterogeneity. </p> <p>We interpreted the I² statistic as per guidance provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004421-bbs2-0061" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>): 0% to 40% might not be important; 30% to 60% represented moderate heterogeneity; 50% to 90% represented substantial heterogeneity; and 75% to 100% represented considerable heterogeneity. </p> </section> <section id="CD004421-sec3-0014"> <h4 class="title">Assessment of reporting biases</h4> <p>We followed the recommendations for testing for funnel plot asymmetry as described in Section 10.4.3.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004421-bbs2-0061" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Funnel plot asymmetry may be due to reporting bias; we addressed this possibility in the <a href="./full#CD004421-sec1-0005">Results</a> and <a href="#CD004421-sec1-0006">Discussion</a> sections of the review. </p> </section> <section id="CD004421-sec3-0015"> <h4 class="title">Data synthesis</h4> <p>For dichotomous outcome data (i.e. toxicity), we used a random‐effects (Mantel‐Haenszel method) model. </p> <p>For time‐to‐event outcome data (i.e. overall survival and disease‐free‐survival), we used a fixed‐effect (exp[(O‐E)/Var] method) analysis. In the case of hormone receptor status subgroup analysis, we analysed the pooled HR using fixed‐effect (generic inverse variance method) analysis. </p> <p>We performed all analyses using Review Manager software (<a href="./references#CD004421-bbs2-0066" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan</a>). </p> <section id="CD004421-sec4-0003"> <h5 class="title">Summary of findings</h5> <p>We used the GRADE approach to assess the quality of evidence for the following six main outcomes: mortality (overall survival), risk of recurrence (disease‐free survival), quality of life, febrile neutropenia, neuropathy (grade 3/4), and cardiotoxicity. We used <a href="./references#CD004421-bbs2-0060" title="GRADEproGDT: GRADEpro Guideline Development Tool [software]. McMaster University, 2015 (developed by Evidence Prime, Inc). Available from www.gradepro.org. ">GRADEproGDT</a> software to develop the 'Summary of findings' table and followed GRADE guidance (<a href="./references#CD004421-bbs2-0060" title="GRADEproGDT: GRADEpro Guideline Development Tool [software]. McMaster University, 2015 (developed by Evidence Prime, Inc). Available from www.gradepro.org. ">GRADEproGDT</a>; <a href="./references#CD004421-bbs2-0067" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlaziouP , et al. Chapter 12. Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). Two review authors (MW, LB) graded the quality of the evidence for this review update. </p> <p>To calculate absolute risk of the control group for time‐to‐event outcomes, we estimated the event rate at a specific time point (five years for OS and DFS) from the Kaplan‐Meier curves or reported event rates. We used a range for baseline event rates (i.e. low‐risk and high‐risk participants). We entered these estimated values into <a href="./references#CD004421-bbs2-0060" title="GRADEproGDT: GRADEpro Guideline Development Tool [software]. McMaster University, 2015 (developed by Evidence Prime, Inc). Available from www.gradepro.org. ">GRADEproGDT</a>, and the corresponding absolute risks for the intervention group with low‐ and high‐risk subgroups at five years were automatically populated by <a href="./references#CD004421-bbs2-0060" title="GRADEproGDT: GRADEpro Guideline Development Tool [software]. McMaster University, 2015 (developed by Evidence Prime, Inc). Available from www.gradepro.org. ">GRADEproGDT</a>. </p> </section> </section> <section id="CD004421-sec3-0016"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed the following post hoc subgroup analyses for overall survival and disease‐free‐survival.</p> <p> <ul id="CD004421-lst1-0005"> <li> <p>Type of taxane (paclitaxel or docetaxel).</p> </li> <li> <p>Sequential or concurrent anthracycline and taxane.</p> </li> <li> <p>Addition or substitution of a taxane.</p> </li> <li> <p>Node positive only, node positive and negative, or node negative only.</p> </li> <li> <p>Longer or the same duration of chemotherapy.</p> </li> <li> <p>Fewer than four or four or more cycles of taxane.</p> </li> <li> <p>Hormone receptor status.</p> </li> </ul> </p> <p>We also conducted post‐hoc subgroup analyses by type of taxane for febrile neutropenia and neuropathy, because neutropenia and neuropathy are toxicities commonly seen when taxanes are used. </p> </section> <section id="CD004421-sec3-0017"> <h4 class="title">Sensitivity analysis</h4> <p>We performed the following sensitivity analyses.</p> <p> <ul id="CD004421-lst1-0006"> <li> <p>Publication status: fully published trials versus trials published in abstract form only. </p> </li> <li> <p>Differences in the definition of DFS: DFS versus relapse‐free survival (RFS); DFS versus time to recurrence (TTR). </p> </li> <li> <p>Risk of bias assessments: low versus high/unclear risk of bias. Studies with more than five of the nine domain judgements with unclear/high risk of bias were assigned an overall assessment of unclear/high risk. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004421-sec1-0005" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004421-sec1-0005"></div> <section id="CD004421-sec2-0008"> <h3 class="title">Description of studies</h3> <section id="CD004421-sec3-0018"> <h4 class="title">Results of the search</h4> <p>For this review update, searching yielded 5118 records from the Specialised Register of the Cochrane Breast Cancer Group, MEDLINE, Embase, and CENTRAL, on 16 July 2018. Searching relevant review papers revealed an additional 16 records, and searching WHO ICTRP and ClinicalTrials.gov revealed one potentially eligible ongoing study. After removing duplicates, we screened the titles and abstracts of the 2802 remaining records and excluded 2735 of them based on information found in the abstract alone. We further assessed the full‐text articles or ongoing trial records for 67 records. We excluded nine records after full‐text review and provided reasons in the <a href="./references#CD004421-sec2-0024" title="">Characteristics of excluded studies</a> table. </p> <p>Of the 58 remaining records, 33 records related to 17 new studies (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>), 14 related to updated data for nine previously included studies (<a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>), eight related to four studies classified as studies 'awaiting classification' due to insufficient reporting of the number of events per treatment arm and relevant effect estimates (<a href="./references#CD004421-bbs2-0044" title="GluzO , ErberR , KatesR , KreipeH , LiedtkeC , PelzE , et al. Predictive value of HER2, topoisomerase‐II (Topo‐II) and tissue inhibitor of metalloproteinases (TIMP‐1) for efficacy of taxane‐based chemotherapy in intermediate risk breast cancer ‐ results of the EC‐Doc Trial. Cancer Research2011;71:P1‐06‐03. NitzU , HuoberJ , LisboaB , HarbeckN , FischerH , MoebusV , et al. Interim results of Intergroup EC‐Doc Trial: a randomized multicentre phase III trial comparing adjuvant CEF/CMF to EC‐Docetaxel in patients with 1‐3 positive lymph nodes. Journal of Clinical Oncology2008;26(Suppl 15):515. NitzU , HuoberJ , LisboaB , HarbeckN , FischerH , MoebusV , et al. Superiority of sequential docetaxel over standard FE100C in patients with intermediate risk breast cancer: survival results of the randomized intergroup phase III trial EC‐Doc. Cancer Research2008;69:78. ">EC‐DOC</a>; <a href="./references#CD004421-bbs2-0046" title="KaderYA , El‐NahasT , SakrA . Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens. OncoTargets and Therapy2013;6:1073‐7. ">Kader</a>; <a href="./references#CD004421-bbs2-0045" title="CardosoF , Piccart‐GebhartMJ , RutgersEJ , LitiereS , Van'tVL , VialeG , et al. Standard anthracycline‐based vs docetaxel‐capecitabine in early breast cancer: results from the chemotherapy randomization (R‐C) of EORTC 10041/BIG3‐04 MINDACT phase III trial. Journal of Clinical Oncology; 2017 Annual meeting of the American Society of Clinical Oncology. 2017; Vol. 35:15 Suppl 1. ">EORTC 10041/BIG 3‐04 MINDACT</a>; <a href="./references#CD004421-bbs2-0047" title="ParticipatingOrganizations . Phase 3 randomized study of adjuvant docetaxel and epirubicin versus adjuvant cyclophosphamide, epirubucin, and fluorouracil with or without trastuzumab in women with nonmetastatic adenocarcinoma of the breast with lymph node invasion. Protocol only2003. RochéH , AllouacheD , RomieuG , BourgeoisH , CanonJ , SerinD , et al. Five‐year analysis of the FNCLCC‐PACS04 Trial: FEC100 vs ED75 for the adjuvant treatment of node positive breast cancer. Cancer Research2009;69:602. SpielmannM , RocheH , DelozierT , CanonJL , RomieuG , BourgeoisH , et al. Trastuzumab for patients with axillary‐node‐positive breast cancer: results of the FNCLCC‐PACS 04 trial. Journal of Clinical Oncology2009;27(36):6129‐34. ">PACS 04</a>), and three were classified as 'ongoing' studies (<a href="./references#CD004421-bbs2-0051" title="KantelhardtE , VetterM , SchmidtM , VeyretC , AugustinD , HanfV , et al. Prospective evaluation of prognostic factors uPA/PAI‐1 in node‐negative breast cancer: phase III NNBC3‐Europe trial (AGO, GBG, EORTC‐PBG) comparing 6 x FEC versus 3 x FEC/3 x docetaxel. BioMed Central2011;11:140. ">NNBC3</a>; <a href="./references#CD004421-bbs2-0049" title="NCT01966471 . A study of Kadcyla (trastuzumab emtansine) plus Perjeta (pertuzumab) following anthracyclines in comparison with Herceptin (trastuzumab) plus Perjeta and a taxane following anthracyclines as adjuvant therapy in patients with operable HER2‐positive primary breast cancer. clinicaltrials.gov/show/NCT01966471 (first received 21 October 2013). ">NCT01966471</a>; <a href="./references#CD004421-bbs2-0050" title="NCT02549677 . Epirubicin versus docetaxel plus cyclophosphamide in lymph node negative, ER‐positive, Her2‐negative breast cancer (ELEGANT). clinicaltrials.gov/ct2/show/NCT02549677 (first received 15 September 2015). ">NCT02549677</a>). </p> <p>The original Cochrane Review identified 23 potentially eligible studies: 12 included studies, three studies 'awaiting classification', and eight ongoing studies (refer to <a href="./references#CD004421-bbs2-0070" title="FergusonT , WilckenN , VaggR , GhersiD , NowakAK . Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD004421.pub2] ">Ferguson 2007</a>). When studies from the original review and those from the review update were combined, review authors had 37 potentially eligible studies involving 29 included studies (referring to 30 treatment comparisons), four studies awaiting inclusion, and four ongoing studies (see PRISMA flowchart: <a href="#CD004421-fig-0001">Figure 1</a>). The PRISMA flowchart for the original review can be found in the previously published version of this review (<a href="./references#CD004421-bbs2-0070" title="FergusonT , WilckenN , VaggR , GhersiD , NowakAK . Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD004421.pub2] ">Ferguson 2007</a>). </p> <div class="figure" id="CD004421-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Review update: study flow diagram." data-id="CD004421-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Review update: study flow diagram.</p> </div> </div> </div> <p>Of the 29 included studies, 27 studies published efficacy data in peer‐reviewed journals (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>), one study had been reported only in abstract form (<a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>), and for one study results were reported in an online thesis (<a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>). For seven studies, we received additional information or clarification of data from the trialists (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>). </p> <p>Since publication of the original review, two studies formally categorised as 'awaiting assessment' ‐ <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a> and <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a> ‐ and six studies categorised as 'ongoing' studies ‐ <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a> ‐ have become included studies. We excluded one previously 'awaiting assessment' study (CALGB 9640: in the review update reclassified as <a href="./references#CD004421-bbs2-0042" title="MooreH , GreenS , GralowJ , BearmanS , LewD , BarlowW , et al. Intensive dose‐dense compared with high‐dose adjuvant chemotherapy for high‐risk operable breast cancer: Southwest Oncology Group/Intergroup Study 9623. Journal of Clinical Oncology2007;25(13):1677‐82. MortimerJE . A comparison of intensive sequential chemotherapy using doxorubicin plus paclitaxel plus cyclophosphamide with high dose chemotherapy and autologous hematopoietic progenitor cell support for primary breast cancer in women with 4‐9 involved axillary lymph nodes, phase 3, Intergroup. Protocol only2001. [CALGB 9960] ">SWOG S9623</a>) due to confounders in the taxane (dose‐dense treatment) and non‐taxane (transplantation) treatment arms. </p> </section> <section id="CD004421-sec3-0019"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD004421-sec2-0023" title="">Characteristics of included studies</a>. </p> <p>For the updated review, we included 29 studies. Of these, seven studies addressed Question 1 (taxane‐containing regimen vs the same regimen without a taxane; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>), nine addressed Question 2 (any taxane‐containing regimen vs any regimen without a taxane; <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>), and 15 addressed Question 3 (any taxane‐containing regimen vs the same regimen with another drug or drugs substituted for the taxane; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). It is noted that <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a> addressed Questions 1 and 3, and <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a> addressed Questions 2 and 3. </p> <p>The NCIC‐CTG MA21 study, which was a three‐arm study with two taxane‐containing arms, reported sufficient data that the study was split into <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> (comparing the taxane regimen of epirubicin/cyclophosphamide followed by paclitaxel (EC‐T) vs fluorouracil/epirubicin/cyclophosphamide (FEC)) and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a> (comparing the taxane regimen of doxorubicin/cyclophosphamide followed by paclitaxel (AC‐T) vs FEC). </p> <p>Of the eight studies classified as 'awaiting classification' or 'ongoing', four addressed Question 2 (<a href="./references#CD004421-bbs2-0044" title="GluzO , ErberR , KatesR , KreipeH , LiedtkeC , PelzE , et al. Predictive value of HER2, topoisomerase‐II (Topo‐II) and tissue inhibitor of metalloproteinases (TIMP‐1) for efficacy of taxane‐based chemotherapy in intermediate risk breast cancer ‐ results of the EC‐Doc Trial. Cancer Research2011;71:P1‐06‐03. NitzU , HuoberJ , LisboaB , HarbeckN , FischerH , MoebusV , et al. Interim results of Intergroup EC‐Doc Trial: a randomized multicentre phase III trial comparing adjuvant CEF/CMF to EC‐Docetaxel in patients with 1‐3 positive lymph nodes. Journal of Clinical Oncology2008;26(Suppl 15):515. NitzU , HuoberJ , LisboaB , HarbeckN , FischerH , MoebusV , et al. Superiority of sequential docetaxel over standard FE100C in patients with intermediate risk breast cancer: survival results of the randomized intergroup phase III trial EC‐Doc. Cancer Research2008;69:78. ">EC‐DOC</a>; <a href="./references#CD004421-bbs2-0045" title="CardosoF , Piccart‐GebhartMJ , RutgersEJ , LitiereS , Van'tVL , VialeG , et al. Standard anthracycline‐based vs docetaxel‐capecitabine in early breast cancer: results from the chemotherapy randomization (R‐C) of EORTC 10041/BIG3‐04 MINDACT phase III trial. Journal of Clinical Oncology; 2017 Annual meeting of the American Society of Clinical Oncology. 2017; Vol. 35:15 Suppl 1. ">EORTC 10041/BIG 3‐04 MINDACT</a>; <a href="./references#CD004421-bbs2-0048" title="ParticipatingOrganizations . Phase 2 randomized study of doxorubicin, cyclophosphamide, and paclitaxel vs cyclophosphamide, thiotepa, and carboplatin in patients with high‐risk primary breast cancer. Protocol only2001. ">NCI‐H99‐0038</a>; <a href="./references#CD004421-bbs2-0049" title="NCT01966471 . A study of Kadcyla (trastuzumab emtansine) plus Perjeta (pertuzumab) following anthracyclines in comparison with Herceptin (trastuzumab) plus Perjeta and a taxane following anthracyclines as adjuvant therapy in patients with operable HER2‐positive primary breast cancer. clinicaltrials.gov/show/NCT01966471 (first received 21 October 2013). ">NCT01966471</a>) and four addressed Question 3 (<a href="./references#CD004421-bbs2-0046" title="KaderYA , El‐NahasT , SakrA . Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens. OncoTargets and Therapy2013;6:1073‐7. ">Kader</a>; <a href="./references#CD004421-bbs2-0050" title="NCT02549677 . Epirubicin versus docetaxel plus cyclophosphamide in lymph node negative, ER‐positive, Her2‐negative breast cancer (ELEGANT). clinicaltrials.gov/ct2/show/NCT02549677 (first received 15 September 2015). ">NCT02549677</a>; <a href="./references#CD004421-bbs2-0051" title="KantelhardtE , VetterM , SchmidtM , VeyretC , AugustinD , HanfV , et al. Prospective evaluation of prognostic factors uPA/PAI‐1 in node‐negative breast cancer: phase III NNBC3‐Europe trial (AGO, GBG, EORTC‐PBG) comparing 6 x FEC versus 3 x FEC/3 x docetaxel. BioMed Central2011;11:140. ">NNBC3</a>; <a href="./references#CD004421-bbs2-0047" title="ParticipatingOrganizations . Phase 3 randomized study of adjuvant docetaxel and epirubicin versus adjuvant cyclophosphamide, epirubucin, and fluorouracil with or without trastuzumab in women with nonmetastatic adenocarcinoma of the breast with lymph node invasion. Protocol only2003. RochéH , AllouacheD , RomieuG , BourgeoisH , CanonJ , SerinD , et al. Five‐year analysis of the FNCLCC‐PACS04 Trial: FEC100 vs ED75 for the adjuvant treatment of node positive breast cancer. Cancer Research2009;69:602. SpielmannM , RocheH , DelozierT , CanonJL , RomieuG , BourgeoisH , et al. Trastuzumab for patients with axillary‐node‐positive breast cancer: results of the FNCLCC‐PACS 04 trial. Journal of Clinical Oncology2009;27(36):6129‐34. ">PACS 04</a>). </p> <section id="CD004421-sec4-0004"> <h5 class="title">Characteristics of patients</h5> <section id="CD004421-sec5-0001"> <h6 class="title">Axillary lymph node involvement</h6> <p>The included studies recruited patient populations with varying risk profiles. Seventeen trials entered participants who were positive for axillary node metastases (i.e. &gt; 85% of included participants were lymph node positive; <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>). Nine studies included participants both with (node positive) and without (node negative) pathologically involved axillary lymph nodes (<a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). Three studies entered participants who were node negative (100%: <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; 94%: <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>). In <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a> and <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>, participants also had a high‐risk factor for recurrence according to 1998 St. Gallen criteria. Baseline characteristics of participants included in the eligible studies are presented in the <a href="./references#CD004421-sec2-0023" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD004421-sec5-0002"> <h6 class="title">Menopausal status</h6> <p>Both premenopausal and postmenopausal women were included in all studies except for three studies (<a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>), which included only postmenopausal patients. <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a> excluded postmenopausal women with hormone receptor‐positive tumours and fewer than four positive axillary nodes. </p> </section> <section id="CD004421-sec5-0003"> <h6 class="title">Hormone receptor status</h6> <p>In nearly all studies, more than 58% of participants had tumours testing positive for oestrogen and/or progesterone receptors, except for <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>, which included participants with triple‐negative breast cancer. </p> </section> </section> <section id="CD004421-sec4-0005"> <h5 class="title">Interventions used in the trials</h5> <p>Twenty‐nine studies involved 41,911 women who were randomised to treatment groups: 21,791 to a taxane‐containing arm, and 20,120 to a non‐taxane‐containing arm. </p> <section id="CD004421-sec5-0004"> <h6 class="title">Chemotherapy</h6> <p>Thirteen of the 29 included studies used paclitaxel (<a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; NCIC‐CTG MA21; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>). The remaining 16 included studies used docetaxel (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>). </p> <p>All studies except four used an anthracycline in both taxane‐containing and non‐taxane‐containing arms (<a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a> compared docetaxel and cyclophosphamide to doxorubicin and cyclophosphamide, <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a> compared paclitaxel alone to the doxorubicin plus cyclophosphamide regimen; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a> compared docetaxel alone to cyclophosphamide, methotrexate, and fluorouracil, and <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a> compared paclitaxel and capecitabine against epirubicin, cyclophosphamide or cyclophosphamide, methotrexate, and fluorouracil. </p> <p>The taxane and anthracycline were administered either sequentially ‐ <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a> ‐ or concurrently ‐ <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>. <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a> randomised participants to four arms ‐ two control and two containing taxanes ‐ to simultaneously examine the effects of concurrent versus sequential administration of taxane and anthracycline. Updated published data from <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a> provided the summary statistics for each group. </p> <p>The total planned dose of anthracycline was the same in both arms in 10 studies (<a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>); it was lower for the taxane‐containing arm in 14 studies (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>). <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a> compared the taxane arm against two different control regimens of FEC or E‐CMF; however the total planned dose of anthracycline was lower in the taxane‐containing arm than in either of the control arms. <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a> used doxorubicin in the taxane arm and epirubicin in the control arm, so doses of anthracycline used were not comparable. <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a> administered dose‐dense chemotherapy in both taxane‐containing and non‐taxane‐containing arms. Dose density was unlikely to be a confounding factor, and the trial was included. </p> <p>Five trials permitted granulocyte colony‐stimulating factor (G‐CSF) as primary prophylaxis. <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a> used primary prophylaxis with G‐CSF and ciprofloxacin with doxorubicin dosed at 90 mg/m², and this was not different between taxane and non‐taxane arms. <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a> used G‐CSF during each cycle (days 3 to 10) with the same dose of G‐CSF given in the two treatment arms. <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a> stated that CSF could be used as per the American Society of Clinical Oncology (ASCO) guidelines, and its use was similar in the two treatment arms. <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a> used primary prophylactic antibiotics for all participants receiving the taxane‐containing regimen and gave primary prophylactic G‐CSF after a protocol amendment. In NCIC‐CTG MA21 (i.e. <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a>), G‐CSF was used as primary prophylaxis in the EC‐T taxane arm but not in the control arm. Use of G‐CSF as primary prophylaxis was identified as a potential confounder when it was used in only one treatment arm. In two studies (<a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>), G‐CSF was recommended in the case of febrile neutropenia. </p> <p>This review did not include neoadjuvant chemotherapy studies. <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a> enrolled patients before surgery and included a neoadjuvant treatment arm. The review included only the two adjuvant chemotherapy arms of this study, one if which contained a taxane drug in the treatment regimen and one that did not. </p> <p>When the taxane‐containing chemotherapy regimens of the included studies was considered, the duration of chemotherapy varied across trials. The addition of extra cycles of chemotherapy to the taxane‐containing regimen has been considered as a potential confounding factor in favour of the taxane‐containing arms of these studies. Fifteen studies, involving 16 treatment comparisons, included chemotherapy treatment arms of equal duration (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>), and eight studies used a taxane‐containing arm that delivered a longer duration or more cycles of chemotherapy than were used in the control arm (<a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>). Three studies involved a taxane‐containing arm of shorter chemotherapy duration than the non‐taxane‐containing arm (<a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>). In <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>, a four‐arm study, the two taxane‐containing arms were of different duration: the sequential taxane arm was longer than the sequential control arm, and the concurrent taxane arm was the same duration as the concurrent control arm. <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>, a three‐arm study, provided two different control regimens whereby one control arm delivered a longer duration of chemotherapy than the second control arm. The control arms were not analysed separately and therefore were not included in analyses related to duration of chemotherapy. </p> </section> <section id="CD004421-sec5-0005"> <h6 class="title">Endocrine therapy</h6> <p>Tamoxifen 20 mg daily for five years for women with oestrogen receptor (ER)‐ and/or progesterone receptor (PR)‐positive tumours was used in most studies, with the following exceptions. <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a> treated all hormone receptor‐positive premenopausal women with a gonadotropin‐releasing hormone (GnRH) analogue for one year in addition to tamoxifen; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a> used tamoxifen for all participants before June 2000, but a subsequent protocol amendment mandated tamoxifen only for hormone receptor‐positive women; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a> initially required tamoxifen treatment post chemotherapy only for postmenopausal women with hormone receptor‐positive or ‐negative tumours and amended the protocol in 1998 to require tamoxifen for premenopausal women with hormone receptor‐positive tumours; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a> included women with triple‐negative breast cancer; in <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>, all women older than 50 years of age at the time of surgery received tamoxifen regardless of hormone receptor status, and only those with positive hormone receptor status received tamoxifen if they were younger than 50 years of age. <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a> also commenced tamoxifen concurrently with chemotherapy. It was not clear from published information whether any other included studies also commenced tamoxifen concurrently with chemotherapy. In eight studies, tamoxifen was initially given to women with ER‐ and/or PR‐positive tumours, but from 2003 to 2007, several protocol amendments allowed postmenopausal women to switch from tamoxifen to aromatase inhibitors (<a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>). <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a> allowed postmenopausal women with hormone receptor‐positive tumours to receive aromatase inhibitors as initial adjuvant therapy or after tamoxifen. All studies used uniform policies for hormonal treatment in both control and experimental arms. </p> </section> <section id="CD004421-sec5-0006"> <h6 class="title">Radiotherapy</h6> <p>Radiotherapy to the breast, when reported, was required when breast‐conserving surgery was performed. This information was not specified in the <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a> and <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a> study reports. Additional radiotherapy was 'as per institution' in <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>, <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>, <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>, <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>, <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>, <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>, <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>, <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>, <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>, <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>, <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>, <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>, <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>, and <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>. In the <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a> study, in some cases MammoSite brachytherapy radiation was permitted if immediately after surgery and before treatment. In <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>, all participants received adjuvant radiotherapy given following completion of chemotherapy or intermittently after completion of 50% of chemotherapy. In <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>, participants received locoregional external beam radiotherapy following their modified radical mastectomy. Axillary or chest wall radiotherapy was given to participants with four or more positive axillary nodes or a primary tumour (T) &gt; 5 cm in <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>, <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>, and <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>. <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a> also gave chest wall radiotherapy to women with a primary T4 tumour. Radiation to the chest wall, supraclavicular area, and internal mammary chain was recommended following mastectomy in <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>. In <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>, axillary or chest wall radiotherapy was not permitted. </p> </section> <section id="CD004421-sec5-0007"> <h6 class="title">Targeted therapy</h6> <p>One study used secondary randomisation to examine the additional question of the addition of trastuzumab to adjuvant chemotherapy for women with human epidermal growth factor receptor 2 (HER2)‐positive tumours following adjuvant chemotherapy (<a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>). <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a> allowed women with HER2‐positive tumours to enter clinical trials for trastuzumab, and <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a> and NCIC‐CTG MA21 (<a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>) recommended trastuzumab for HER2‐positive tumours after 2005. <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a> included women with HER2‐positive tumours (19% of the population) who received adjuvant trastuzumab for one year after chemotherapy based on results from the HERA trial. </p> </section> </section> <section id="CD004421-sec4-0006"> <h5 class="title">Outcomes assessed in trials</h5> <p>The median follow‐up for participants ranged from 24 months in <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a> to 163 months (estimated follow‐up) in <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>. </p> <p>Four studies reported overall survival as a primary outcome (<a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>), and 26 studies reported DFS (or RFS, distant disease‐free survival (DDFS) if reported) as the primary outcome. Both <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a> and <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a> had two primary outcomes (overall survival and DFS). </p> <p>Not all trials reported data on all outcomes for this review. Two studies did not report complete data on overall survival and were not included for this part of the meta‐analysis (<a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>). For NCIC‐CTG Ma21, the number of events had not been reached to conduct a formal statistical comparison for survival analysis, and for <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>, overall survival data were not reported in abstract form nor in the full trial publication. All trials reported on DFS; however the terminology and definitions used differed slightly between trials (<a href="#CD004421-tbl-0014">Table 1</a>). Definitions were the same for both experimental and control arms of each trial, and, for the purposes of this review, all breast cancer recurrence events under the different definitions were combined. </p> <div class="table" id="CD004421-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Definition of "disease‐free survival"</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revised to iDFS (in 2016) in line with Standardized Definitions for Efficacy End Points (STEEP), where DFS referred to all invasive ipsilateral, regional, contralateral, and distant disease recurrences, second primary tumours, and death from any cause as events, and all non‐invasive in situ cancer events were excluded </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation to date of clinical relapse (histological or radiological evidence), a second cancer (except skin cancer other than melanoma or carcinoma in situ of breast or cervix), or death </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation until first date of local, regional, or distant relapse; diagnosis of a second primary cancer, including contralateral invasive breast cancer; or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from date of random assignment to date of locoregional and/or distant release</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from <i>study entry</i> until local recurrence, distant relapse, or death without relapse, whichever occurred first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation to date of first locoregional recurrence, first distant metastasis, or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from date of randomisation to locoregional recurrence, distant recurrence, new primary breast cancer, or death </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Freedom from progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported in trial publication</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interval between randomisation and locoregional or distant relapse or contralateral invasive breast cancer or second primary invasive non‐breast cancer or ipsilateral or contralateral in situ ductal carcinoma or death without cancer, whichever occurred first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from date of random assignment to date of invasive breast cancer recurrence, invasive contralateral breast cancer, or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrence‐free survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation to date of detection of local or distant relapse (histological or radiological evidence) or contralateral invasive breast cancer or death without recurrence </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from random assignment to date of local, regional, or metastatic relapse; date of a second primary malignancy; or death form any cause, whichever occurred first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from date of randomisation to date of local, regional, or metastatic relapse; diagnosis of second primary cancer or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>According to the definition of invasive disease‐free survival (IDFS) in the STEEP system </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation to first relapse (local, regional, distant), contralateral breast cancer, or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from date of randomisation to date of local recurrence, distant metastases, contralateral breast cancer, second primary malignancy, or death from any cause, whichever occurred first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation until local recurrence, distant relapse, or death (without relapse) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation to date of breast cancer recurrence (local, regional, or distant), invasive contralateral breast cancer, non‐breast second primary cancer, or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>iDFS and DDFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any local invasive or distant recurrence of breast cancer, any contralateral breast cancer, any second malignancy, and any death irrespective of its cause for iDFS </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from random assignment to time of recurrence of the primary breast cancer (local, nodal, metastatic). Patients with contralateral breast cancer, second malignancy, non‐disease‐related death were censored </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from random assignment to time of recurrence of the primary breast cancer (local, nodal, metastatic). Patients with contralateral breast cancer, second malignancy, non‐disease‐related death were censored </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation until local, regional, or distant treatment failure, contralateral breast cancer, non‐breast second primary cancer, or death </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation until first relapse (local, regional, or distant), contralateral breast cancer, or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TTR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to locoregional relapse, contralateral breast cancer, or distant metastasis, whichever occurs first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from <i>study entry</i> to first local recurrence or distant metastasis, or death as a result of any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation until first relapse (locoregional or distant), contralateral breast cancer, or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation to first invasive relapse, new primary breast cancer (ipsilateral or contralateral), or death form any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from date of randomisation to local or distant recurrence or contralateral breast cancer or second primary malignancy or death from any case, whichever occurred first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time between randomisation and date of first documented disease recurrence or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from <i>first dose of chemotherapy</i> until date of any recurrence of breast cancer, a new second breast cancer or any other type of cancer, death due to any cause without relapse or recurrence of breast cancer, or date of last patient contact </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>DFS: disease‐free survival<br/> EFS: event‐free survival<br/> RFS: relapse‐free survival<br/> TTR: time to recurrence </p> </div> </div> <p>All 29 studies reported some toxicity data; however data from one study could not be extracted and included in this review (<a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>). This study presented toxicity data per week of treatment. </p> <p>Seven studies presented quality of life measures (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>). <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>, <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>, and NCIC‐CTG MA21 also listed quality of life as a secondary outcome; however these data have yet to be reported. </p> </section> </section> <section id="CD004421-sec3-0020"> <h4 class="title">Excluded studies</h4> <p>Nine studies were excluded from this review update. One record reported results for <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a> but was found to be a trial commentary (<a href="./references#CD004421-bbs2-0032" title="DangC . Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Current Breast Cancer Reports2009;1(1):1‐2. ">Dang</a>), and another record reported on the prognostic and predictive significance of subtyping in the <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a> study (<a href="./references#CD004421-bbs2-0035" title="HughJ , HansonJ , CheangMCU , NielsenTO , PerouCM , DumontetC , et al. Breast cancer subtypes and response to docetaxel in node‐positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. Journal of Clinical Oncology2009;27(8):1168‐76. ">Hugh</a>). Two studies involved neoadjuvant chemotherapy: in <a href="./references#CD004421-bbs2-0031" title="AlbertJM , BuzdarAU , GuzmanR , AllenPK , StromEA , PerkinsGH , et al. Prospective randomized trial of 5‐fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Research and Treatment2011;128(2):421‐7. ">Albert</a>, adjuvant data were unable to be separated from neoadjuvant data, and in <a href="./references#CD004421-bbs2-0039" title="BearHD , AndersonS , SmithRE , GeyerCEJr , MamounasEP , FisherB , et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B‐27. Journal of Clinical Oncology2006;24(13):2019‐27. ">NSABP B‐27</a>, all participants received neoadjuvant chemotherapy before receiving adjuvant taxane. In four studies it was observed that all treatment arms received taxane therapy (<a href="./references#CD004421-bbs2-0038" title="NCT02838225 . DA versus DAC as postoperative adjuvant treatment for early‐stage breast cancer. clinicaltrials.gov/ct2/show/NCT02838225 (first received 20 July 2016). ">NCT02838225</a>; <a href="./references#CD004421-bbs2-0040" title="SparanoJA , ZhaoF , MartinoS , LigibelJA , PerezEA , SaphnerT , et al. Long‐term follow‐up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. Journal of Clinical Oncology2015;33(21):2353‐60. ">Sparano 2015</a>; <a href="./references#CD004421-bbs2-0041" title="BuddGT , BarlowWE , MooreHCF , HobdayTJ , StewartJA , IsaacsC , et al. First analysis of SWOG S0221: a phase III trial comparing chemotherapy schedules in high‐risk early breast cancer. Journal of Clinical Oncology2011;29:1004. ">SWOG S0221</a>; <a href="./references#CD004421-bbs2-0043" title="WildiersH . A randomized phase II trial exploring feasibility of densification and optimal sequencing of postoperative adjuvant fluorouracil, epirubicin plus cyclophosphamide (FEC) and docetaxel chemotherapy in patients with high risk primary operable breast cancer. Physician Data Query (PDQ)2006. ">Wildiers</a>). In <a href="./references#CD004421-bbs2-0042" title="MooreH , GreenS , GralowJ , BearmanS , LewD , BarlowW , et al. Intensive dose‐dense compared with high‐dose adjuvant chemotherapy for high‐risk operable breast cancer: Southwest Oncology Group/Intergroup Study 9623. Journal of Clinical Oncology2007;25(13):1677‐82. MortimerJE . A comparison of intensive sequential chemotherapy using doxorubicin plus paclitaxel plus cyclophosphamide with high dose chemotherapy and autologous hematopoietic progenitor cell support for primary breast cancer in women with 4‐9 involved axillary lymph nodes, phase 3, Intergroup. Protocol only2001. [CALGB 9960] ">SWOG S9623</a>, dose‐dense chemotherapy in the taxane‐containing arm and high‐dose escalated chemotherapy with autologous haematopoietic progenitor cell transplantation in the non‐taxane arm were viewed as confounders, and the study was excluded. See <a href="./references#CD004421-sec2-0024" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD004421-sec2-0009"> <h3 class="title">Risk of bias in included studies</h3> <p>Refer to <a href="#CD004421-fig-0002">Figure 2</a> for a summary of the risk of bias judgements for the included studies for each risk of bias domain. </p> <div class="figure" id="CD004421-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004421-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD004421-sec3-0021"> <h4 class="title">Allocation</h4> <p>The 29 studies, which related to 30 treatment comparisons, were described as randomised. The method of random sequence generation was described adequately (i.e. with low risk of bias) in 28 studies referring to 29 treatment comparisons (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>). These studies reportedly used stratified randomisation, permuted block design, or minimisation. It was not possible to accurately assess the method of random sequence generation in one study owing to lack of information presented in the published trial report (<a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). This study was classified as having unclear risk of bias. </p> <p>Twenty‐three of the 29 studies were at low risk of bias for allocation concealment. These studies described central randomisation systems (computer or telephone/fax) (<a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; NCIC‐CTG MA21 (<a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>); <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>;<a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>). Six studies did not describe methods of allocation concealment or did not provide sufficient detail in the trial publication or abstract and were judged as having unclear risk of bias (<a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). </p> </section> <section id="CD004421-sec3-0022"> <h4 class="title">Blinding</h4> <p>Twenty‐one studies were described as 'open label' or 'non‐blinded' (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>), and eight studies provided no information in the abstract or trial publication to allow a firm conclusion on whether they were 'open‐label' studies (<a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). Performance bias due to lack of blinding of participants and personnel could not be ruled out, and these 29 studies were judged as having unclear risk of bias for this domain. </p> <p>Detection bias was assessed by grouping outcomes with similar risks of bias: (1) overall survival, (2) disease‐free survival and toxicity, and (3) quality of life. For overall survival, lack of blinding was perceived as unlikely to have an impact on this outcome assessment. Therefore all studies were perceived to be at low risk of bias. For outcome measures that were more likely to be influenced by lack of blinding, that is, disease‐free survival and toxicity, we assessed whether outcome assessments were confirmed through imaging and biochemical tests and reviewed by independent panels/adjudication committees in each study. All 29 included studies were at unclear risk of bias because these outcomes were measured through scans and blood tests with no independent clinical review group. Quality of life measures were likely to be affected by lack of blinding to treatment. Seven of the ten studies that had planned to collect QoL data actually reported these data (data provided: <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; data not reported: <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>). Quality of life questionnaires were completed by participants; the seven studies that reported these data were therefore considered to be at high risk. </p> </section> <section id="CD004421-sec3-0023"> <h4 class="title">Incomplete outcome data</h4> <p>Twenty‐three studies described intention‐to‐treat analysis and minimal patient loss to follow‐up that was accounted for; therefore we judged them to be at low risk of bias: <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>, <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>, <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>, <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>, <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>, <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>, <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>, <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>, <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>, <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>, <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>, <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>, <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>, <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>, <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>, <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>, <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>, <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>, <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>, <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>, <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>, <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>, and <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>. Four studies were judged as having unclear risk of bias due to insufficient or no information provided for their analysis plan (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>), and two studies were considered at high risk of bias for this domain due to no intention‐to‐treat analyses and missing data with no reasons provided (<a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>). </p> </section> <section id="CD004421-sec3-0024"> <h4 class="title">Selective reporting</h4> <p>Twenty‐three studies, relating to 24 treatment comparisons, reported results for outcomes listed in the methods section of the trial publication (<a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>) or provided a trial registration record with listed outcomes found in the methods and results sections of the trial publication (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). In the remaining six studies, there was partial reporting of results (i.e. for QoL) or some changes were noted in the primary or secondary outcomes (<a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>); these studies were ranked at unclear risk of bias for this domain. <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a> was judged as having high risk of bias for this domain, as data related to overall survival were not reported, although OS was listed as a secondary outcome in the trial publication. </p> </section> <section id="CD004421-sec3-0025"> <h4 class="title">Other potential sources of bias</h4> <p>Treatment groups were well balanced in most studies (low risk of bias: <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). When minor baseline imbalances (such as differences in tumour size and in hormone receptor status across treatment groups) were reported, these were considered by the review authors to be unlikely to bias trial outcomes; these trials therefore were ranked as having unclear risk (<a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>). </p> </section> </section> <section id="CD004421-sec2-0010"> <h3 class="title" id="CD004421-sec2-0010">Effects of interventions</h3> <p>See: <a href="./full#CD004421-tbl-0001"><b>Summary of findings for the main comparison</b> Taxane‐containing chemotherapy vs any chemotherapy without taxane for early breast cancer</a> </p> <p>Refer to <a href="./full#CD004421-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD004421-sec3-0026"> <h4 class="title">Overall survival</h4> <p>High‐quality evidence was obtained from 27 studies for analysis of overall survival (OS). The NCIC‐CTG MA21 ‐ <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a>; <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a> ‐ and <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a> studies did not report sufficient OS data to allow indirect calculations of the hazard ratio (HR) and confidence interval (CI). A total of 39,180 women were included in the overall survival analysis, with 6501 deaths reported. Taxane‐containing regimens improved survival when compared to non‐taxane‐containing controls (HR 0.87, 95% CI 0.83 to 0.92; P &lt; 0.001; high‐certainty evidence; <a href="./references#CD004421-fig-00101" title="">Analysis 1.1</a>; <a href="#CD004421-fig-0003">Figure 3</a>). Heterogeneity across trials was moderate (heterogeneity I² = 35%; P = 0.04). </p> <div class="figure" id="CD004421-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Overall effect of taxanes, outcome: 1.1 Overall survival ‐ all studies." data-id="CD004421-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Overall effect of taxanes, outcome: 1.1 Overall survival ‐ all studies. </p> </div> </div> </div> </section> <section id="CD004421-sec3-0027"> <h4 class="title">Disease‐free survival</h4> <p>High‐certainty evidence was obtained from all 29 studies, involving 30 comparisons, for analysis of disease‐free survival (DFS). In this review, DFS analysis included freedom from progression (as measured in <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>), time to recurrence (as measured in <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>), event‐free survival (as per <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>), and recurrence‐free survival (as measured in <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>, <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>, <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>, and <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>). Although <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a> reported relapse‐free survival (RFS) and <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a> reported event‐free survival (EFS), these definitions were considered similar to those reported as DFS in other studies. Two studies ‐ <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a> ‐ specifically excluded ductal carcinoma in situ (DCIS) and one study included DCIS in its DFS definition (<a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>). See <a href="#CD004421-tbl-0014">Table 1</a> for the definition of DFS used in each study. </p> <p>A total of 41,909 women from 29 studies were included in the DFS analysis, with 10,271 reported events. Taxane‐containing treatment improved disease‐free survival compared to control (HR 0.88, 95% CI 0.85 to 0.92; P &lt; 0.001; high‐certainty evidence; <a href="./references#CD004421-fig-00102" title="">Analysis 1.2</a>; <a href="#CD004421-fig-0004">Figure 4</a>). Heterogeneity across studies was substantial (heterogeneity I² = 59%; P &lt; 0.001). </p> <div class="figure" id="CD004421-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Overall effect of taxanes, outcome: 1.2 Disease‐free survival: all studies." data-id="CD004421-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Overall effect of taxanes, outcome: 1.2 Disease‐free survival: all studies. </p> </div> </div> </div> <p>We noted differences among the definitions used by each study, with death and contralateral breast cancer at times not counted among DFS events; in the first instance, we judged that this would have a minor impact on DFS analysis. To test this, we conducted a post‐hoc sensitivity analysis while excluding <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>, <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>, <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a> and <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>. The result did not change significantly (HR 0.86, 95% CI 0.82 to 0.89; P &lt; 0.001; <a href="./references#CD004421-fig-00103" title="">Analysis 1.3</a>), and heterogeneity was moderate (I² = 40%; P = 0.02). The definition of freedom from progression in <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a> would typically be consistent with DFS as defined in the other included studies; therefore we did not conduct a sensitivity analysis. </p> <section id="CD004421-sec4-0007"> <h5 class="title">Subgroup analysis</h5> <p>Several post‐hoc subgroup analyses were performed in a side‐by‐side observational manner and are reported below. This exercise has limitations, although it was undertaken to address clinically relevant questions. Tests for interaction have not been performed as no differences between subgroups have been postulated. </p> </section> <section id="CD004421-sec4-0008"> <h5 class="title">Type of taxane</h5> <p>The two taxane drugs were analysed in separate groups in this post‐hoc analysis to assess whether there was a difference in efficacy between them. </p> <p>Sixteen studies used docetaxel: 15 studies provided sufficient data for OS analyses (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>), and all 16 studies provided DFS data for analyses (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). The remaining 13 studies used paclitaxel; OS data were available for 12 studies (<a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>), and DFS data were available for 13 studies with 14 treatment comparisons (<a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>). Both types of taxane showed a significant HR favouring taxane treatment over controls for both OS and DFS. </p> <section id="CD004421-sec5-0008"> <h6 class="title">Overall survival</h6> <p>The docetaxel group included 22,105 women, and the paclitaxel group included 17,075 women. The HR for the docetaxel group was 0.86 (95% CI 0.81 to 0.92; P &lt; 0.001; <a href="./references#CD004421-fig-00201" title="">Analysis 2.1</a>) with moderate heterogeneity (I² = 37%; P = 0.07), which was comparable to the paclitaxel group at HR 0.89 (95% CI 0.82 to 0.96; P = 0.003; <a href="./references#CD004421-fig-00201" title="">Analysis 2.1</a>) with moderate heterogeneity (I² = 37%; P = 0.10). </p> </section> <section id="CD004421-sec5-0009"> <h6 class="title">Disease‐free survival</h6> <p>The docetaxel group included 22,730 women, and the paclitaxel group had 19,179 women. The HR for the docetaxel group was 0.87 (95% CI 0.82 to 0.91; P &lt; 0.001; <a href="./references#CD004421-fig-00202" title="">Analysis 2.2</a>) with moderate heterogeneity (I² = 39%; P = 0.06), and the HR for the paclitaxel group was 0.91 (95% CI 0.85 to 0.96; P = 0.002; <a href="./references#CD004421-fig-00202" title="">Analysis 2.2</a>) with substantial heterogeneity (I² = 71%; P &lt; 0.001). </p> </section> </section> <section id="CD004421-sec4-0009"> <h5 class="title">Weekly versus three‐weekly taxane</h5> <p>A post‐hoc analysis was conducted to examine the difference in efficacy between weekly versus three‐weekly administered taxanes. All studies that administered docetaxel did so using a three‐weekly regimen, except <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>, which administered weekly docetaxel, so efficacy data for docetaxel were not further examined. Two studies that administered paclitaxel were not included in this post‐hoc analysis as they could not be classified as weekly or three‐weekly regimens: <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a> administered paclitaxel either fortnightly or in three‐weekly cycles, and <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a> used fortnightly paclitaxel for all women in the taxane group. </p> <section id="CD004421-sec5-0010"> <h6 class="title">Overall survival</h6> <p>Four studies (4176 women) provided a regimen of weekly paclitaxel in the taxane arm (<a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>). Analysis of these studies yielded an HR of 0.80, favouring the taxane arm (95% CI 0.65 to 0.98; P = 0.7; <a href="./references#CD004421-fig-00301" title="">Analysis 3.1</a>), with no heterogeneity (P = 0.70). Six studies (8433 women) administered paclitaxel every three weeks (<a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>), with HR of 0.86 favouring taxane (95% CI 0.78 to 0.95; P = 0.002; <a href="./references#CD004421-fig-00301" title="">Analysis 3.1</a>), and with no significant heterogeneity (I² = 15%; P = 0.32). </p> </section> <section id="CD004421-sec5-0011"> <h6 class="title">Disease‐free survival</h6> <p>Four studies (4176 women) that administered weekly paclitaxel ‐ <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a> ‐ gave a combined HR of 0.79 favouring the taxane (95% CI 0.67 to 0.92; P = 0.003; <a href="./references#CD004421-fig-00302" title="">Analysis 3.2</a>), with no heterogeneity (I² = 0%; P = 0.42). Six studies (8433) provided a regimen of paclitaxel administered three‐weekly (<a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>). Analysis of these studies revealed an HR of 0.85 (95% CI 0.79 to 0.92; P &lt; 0.001; <a href="./references#CD004421-fig-00302" title="">Analysis 3.2</a>), with significant heterogeneity (I² = 62%; P &lt; 0.02). </p> </section> </section> <section id="CD004421-sec4-0010"> <h5 class="title">Sequential or concurrent taxane and anthracycline</h5> <p>Taxane treatment was given sequentially or concurrently with anthracycline, and it is unclear whether this scheduling impacts efficacy. Analysis was performed to examine this question. Toxicity differences between the two schedules are discussed separately. </p> <section id="CD004421-sec5-0012"> <h6 class="title">Overall survival</h6> <p>Eighteen studies (24,764 women) administered the taxane and anthracycline sequentially in the experimental arm (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>). Analysis of these studies demonstrated an HR of 0.86 favouring the taxane‐containing group (95% CI 0.81 to 0.91; P &lt; 0.001; <a href="./references#CD004421-fig-00401" title="">Analysis 4.1</a>), with no significant heterogeneity (I² = 17%; P = 0.25). Six studies (8839 women) administered the taxane and anthracycline concurrently in the experimental arm (<a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>). Analysis of these studies revealed an HR of 0.86, favouring the taxane‐containing group (95% CI 0.78 to 0.94; P = 0.002; <a href="./references#CD004421-fig-00401" title="">Analysis 4.1</a>), with no heterogeneity (P = 0.37). </p> </section> <section id="CD004421-sec5-0013"> <h6 class="title">Disease‐free survival</h6> <p>Nineteen studies with 20 treatment comparisons (26,866 women) administered the taxane and anthracycline sequentially in the experimental arm (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>). The estimated HR from analysis of these studies was 0.86, favouring the taxane‐containing group (95% CI 0.82 to 0.90; P &lt; 0.001; <a href="./references#CD004421-fig-00402" title="">Analysis 4.2</a>), with moderate heterogeneity (I² = 51%; P = 0.005). Seven studies (9466 women) administered the taxane and anthracycline concurrently in the experimental arm (<a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>). The estimated HR was 0.89, favouring the taxane‐containing group (95% CI 0.83 to 0.97; P &lt; 0.001; <a href="./references#CD004421-fig-00402" title="">Analysis 4.2</a>), with moderate heterogeneity (I² = 51%; P = 0.05). <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a> reported both sequential and concurrent administration arms; thus separately reported arms were included in this analysis. </p> </section> </section> <section id="CD004421-sec4-0011"> <h5 class="title">Addition of taxane or substitution of taxane</h5> <p>This analysis separated groups into those where a taxane was added to control chemotherapy studies (Question 1) and those where a taxane was substituted for part of the control chemotherapy (Question 3). This analysis was performed, as it has been postulated that benefit from taxane treatment could be due in part to the addition of an extra non‐cross‐resistant drug rather than to superior efficacy of the taxane itself. </p> <section id="CD004421-sec5-0014"> <h6 class="title">Overall survival</h6> <p>Data were available for seven studies (10,842 women) designed such that the experimental arm received a taxane administered in addition to control chemotherapy (<a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>). Analysis of these studies yielded an HR of 0.84, favouring the taxane‐containing group (95% CI 0.77 to 0.92; P &lt; 0.001; <a href="./references#CD004421-fig-00501" title="">Analysis 5.1</a>), with no heterogeneity (P = 0.60). Data were available for 13 (16,196 women) of 15 eligible studies, and these studies were designed with the experimental arm given a taxane substituted for one or more of the drugs from the control (<a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). This group also had an HR of 0.80 in favour of the taxane‐containing treatments (95% CI 0.74 to 0.86; P &lt; 0.001; <a href="./references#CD004421-fig-00501" title="">Analysis 5.1</a>), with no significant heterogeneity (I² = 6%; P = 0.38). </p> </section> <section id="CD004421-sec5-0015"> <h6 class="title">Disease‐free survival</h6> <p>Seven studies (10,842 women) were designed such that the experimental arm received a taxane administered in addition to control chemotherapy (<a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>). For these studies, an HR of 0.84 favoured the taxane‐containing group (95% CI 0.78 to 0.90; P &lt; 0.001), with no heterogeneity (P = 0.66). Fourteen studies included 16,823 women and were designed with the experimental arm receiving a taxane substituted for one or more of the drugs from the control (<a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). This group also had an HR of 0.83, in favour of taxane‐containing treatments (95% CI 0.78 to 0.88; P &lt; 0.001), with moderate heterogeneity (I² = 47%; P = 0.03). </p> </section> </section> <section id="CD004421-sec4-0012"> <h5 class="title">Duration of chemotherapy</h5> <p>Studies have been examined post‐hoc to examine whether a longer duration of chemotherapy in the taxane arm may explain the observed improvement in outcomes. Groups were divided according to duration of total planned treatment rather than the total number of planned cycles to account for variation in cycle length between studies. <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a> included two taxane‐containing arms ‐ one with longer duration and the other with the same duration as the control arm. As these arms were reported separately for OS and DFS, they are included in the analyses below. </p> <section id="CD004421-sec5-0016"> <h6 class="title">Overall survival</h6> <p>Nine studies (13,865 women) included a taxane‐containing experimental arm that was of longer duration than the control arm (<a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>). Analysis of these studies revealed an HR of 0.84, favouring the taxane‐containing group (95% CI 0.77 to 0.91; P &lt; 0.001; <a href="./references#CD004421-fig-00601" title="">Analysis 6.1</a>), with no heterogeneity (P = 0.69). Fourteen studies (18,660 women) were designed with a taxane‐containing experimental arm of the same duration as the control arm (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). This group also had an HR of 0.87 in favour of taxane‐containing treatments (95% CI 0.81 to 0.94; P &lt; 0.001; <a href="./references#CD004421-fig-00601" title="">Analysis 6.1</a>), with moderate heterogeneity (I² = 52%; P = 0.01). </p> </section> <section id="CD004421-sec5-0017"> <h6 class="title">Disease‐free survival</h6> <p>Nine studies (13,865 women) were designed to include a taxane‐containing experimental arm of longer duration than the control arm (<a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>). The HR for DFS was 0.83, favouring the taxane‐containing group (95% CI 0.77 to 0.88; P &lt; 0.001; <a href="./references#CD004421-fig-00602" title="">Analysis 6.2</a>), with no heterogeneity (P = 0.85). Sixteen studies (17 treatment comparisons) involving 21,391 women were designed with the taxane‐containing arm having the same duration as the control arm (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). An HR of 0.90 in favour of the taxane‐containing arms was found for this group of studies (95% CI 0.85 to 0.96; P &lt; 0.001; <a href="./references#CD004421-fig-00602" title="">Analysis 6.2</a>), with substantial heterogeneity (I² = 70%; P &lt; 0.001). </p> </section> </section> <section id="CD004421-sec4-0013"> <h5 class="title">Number of cycles of taxane‐containing chemotherapy</h5> <p>This post‐hoc analysis examined studies that administered three cycles of the taxane drug in comparison with studies that used four or more cycles of taxane in the experimental arm. This was done to determine if the number of cycles of taxane impacted efficacy. This analysis had limitations due to heterogeneity between studies with the use of different control regimens and varying doses and scheduling of the taxane drug. <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a> included two taxane arms ‐ one administered three cycles of taxane, and the other four. These arms were separately reported for DFS and therefore were included separately in this analysis. Although <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a> administered paclitaxel weekly for 12 weeks, this is often considered as three weeks of paclitaxel (weekly) multiplied by four, and thus is classified as four cycles of taxane. <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a> and <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a> used eight weekly doses of paclitaxel and could not be classified in either group. These results were not included in the analysis. </p> <section id="CD004421-sec5-0018"> <h6 class="title">Overall survival</h6> <p>Seven studies (6551 women) used three cycles of taxane treatment in the experimental arm (<a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>), reporting an HR of 0.77 favouring the taxane‐containing group (95% CI 0.69 to 0.86; P &lt; 0.001; <a href="./references#CD004421-fig-00701" title="">Analysis 7.1</a>), with no heterogeneity (P = 0.60). Nineteen studies (29,458 women) ‐ <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a> ‐ used four or more cycles of taxane and found an HR of 0.91 in favour of taxane‐containing treatments (95% CI 0.86 to 0.96; P &lt; 0.001; <a href="./references#CD004421-fig-00701" title="">Analysis 7.1</a>), with moderate heterogeneity (I² = 32%; P = 0.09). </p> </section> <section id="CD004421-sec5-0019"> <h6 class="title">Disease‐free survival</h6> <p>Seven studies (6551 women) used three cycles of taxane treatment in the taxane arm (<a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>). Analysis of these studies revealed an HR of 0.80, favouring the taxane‐containing group (95% CI 0.73 to 0.88; P &lt; 0.001; <a href="./references#CD004421-fig-00702" title="">Analysis 7.2</a>), with moderate heterogeneity (I² = 48%; P = 0.07). Twenty‐one studies (32,187 women) with 22 treatment comparisons ‐ <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a> ‐ used four or more cycles of taxane and also found an HR for DFS of 0.91 in favour of taxane‐containing treatments (95% CI 0.87 to 0.95; P &lt; 0.001; <a href="./references#CD004421-fig-00702" title="">Analysis 7.2</a>), with moderate heterogeneity (I² = 57%; P &lt; 0.001). </p> </section> </section> <section id="CD004421-sec4-0014"> <h5 class="title">Lymph node status</h5> <p>Variations in inclusion criteria between studies may have had an impact on the risk of recurrence. Analysis was performed to examine whether there was any indication that the benefit of taxane‐containing treatment was greater in studies that included only lymph node‐positive women as compared to studies that included both lymph node‐negative and lymph node‐positive women. It was identified that studies allowing participation of women without lymph node involvement generally required other high‐risk features for inclusion. </p> <section id="CD004421-sec5-0020"> <h6 class="title">Overall survival</h6> <p>Seventeen studies included women with positive axillary lymph node metastasis (22,055 women; 4152 deaths) (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>). Analysis of these studies revealed an HR of 0.83, favouring the taxane‐containing group (95% CI 0.78 to 0.88; P &lt; 0.001; <a href="./references#CD004421-fig-00801" title="">Analysis 8.1</a>), with nominal heterogeneity (I² = 3%; P = 0.41). Seven studies included participants both with and without lymph node metastases (10,269 women; 1952 deaths) (<a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). Analysis of these studies yielded an HR of 0.95, with taxane‐containing groups resulting reporting little to no difference in survival compared to non‐taxane‐containing groups (95% CI 0.87 to 1.04; P = 0.26; <a href="./references#CD004421-fig-00801" title="">Analysis 8.1</a>), with no significant heterogeneity (I² = 12%, P = 0.34). Three studies included women with no lymph node metastases (6856 women; 397 deaths) (<a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>); researchers found an HR of 1.08, indicating that the taxane‐containing treatment group showed little to no difference in survival compared to the control group (95% CI 0.89 to 1.32; P = 0.43; <a href="./references#CD004421-fig-00801" title="">Analysis 8.1</a>), with substantial heterogeneity (I² = 62%; P = 0.07). </p> </section> <section id="CD004421-sec5-0021"> <h6 class="title">Disease‐free survival</h6> <p>Seventeen studies included participants with positive axillary lymph node metastasis (22,055 women; 6575 events) (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>). The estimated HR was 0.84, favouring the taxane‐containing group (95% CI 0.80 to 0.88; P &lt; 0.001; <a href="./references#CD004421-fig-00802" title="">Analysis 8.2</a>), with moderate heterogeneity (I² = 32%; P = 0.10). Nine studies with 10 treatment comparisons included women both with and without lymph node involvement (12,998 women; 2929 events) (<a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). The estimated HR was 0.95 and did not demonstrate a difference in risk of disease progression between taxane and non‐taxane groups (95% CI 0.88 to 1.02; P = 0.15; <a href="./references#CD004421-fig-00802" title="">Analysis 8.2</a>), with moderate heterogeneity (I² = 55%; P = 0.02). Three studies ‐ <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a> ‐ included only women with negative lymph nodes (6856 women; 767 events); the pooled analysis did not demonstrate a difference in risk of disease progression between taxane‐containing and control chemotherapy regimens, with an estimated HR of 0.99 (95% CI 0.86 to 1.14; P = 0.85; <a href="./references#CD004421-fig-00802" title="">Analysis 8.2</a>), with substantial heterogeneity (I² = 87%; P &lt; 0.001). </p> </section> </section> <section id="CD004421-sec4-0015"> <h5 class="title">Hormone receptor status</h5> <p>This post‐hoc analysis examined studies that reported treatment effects by subgroups for hormone receptor status. This analysis was performed to see whether there was any indication of benefit for taxane‐containing regimens in hormone receptor‐positive women as compared to women with hormone receptor‐negative tumours. Fifteen studies, 16 treatment comparisons, did not test or adequately report the effects of taxanes by hormone receptor subgroup for time‐to‐event analysis (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>). </p> <section id="CD004421-sec5-0022"> <h6 class="title">Overall survival</h6> <p>Five studies reported sufficient data for the subgroups of hormone receptor‐positive and ‐negative status (<a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>). The subgroup of participants with hormone receptor‐positive tumours showed an HR of 0.79, in favour of taxane‐containing treatments (95% CI 0.70 to 0.89; P &lt; 0.001; <a href="./references#CD004421-fig-00901" title="">Analysis 9.1</a>), with no heterogeneity (P = 0.61). The subgroup of participants with hormone receptor‐negative tumours showed that taxane‐containing regimens resulted in little to no difference in survival compared to non‐taxane‐containing regimens (HR 0.88, 95% CI 0.73 to 1.05; P = 0.15; <a href="./references#CD004421-fig-00901" title="">Analysis 9.1</a>), with no heterogeneity (P = 0.56). </p> </section> <section id="CD004421-sec5-0023"> <h6 class="title">Disease‐free survival</h6> <p>Eleven studies published sufficient data on hormone receptor subgroups (<a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). For the subgroup of participants with hormone receptor‐positive (or oestrogen receptor‐positive only in some studies: <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>) tumours, taxane‐containing regimens appeared to reduce the risk of disease recurrence compared to non‐taxane‐containing regimens, with an HR of 0.91 (95% CI 0.85 to 0.97; P = 0.005; 11 studies; 3367 participants; <a href="./references#CD004421-fig-00902" title="">Analysis 9.2</a>), although with substantial heterogeneity (I² = 56%; P = 0.01). The subgroup of participants with hormone receptor‐negative tumours was found to have a similar result in favour of the taxane‐containing regimen, with an HR of 0.80 (95% CI 0.73 to 0.88; P &lt; 0.001; 12 studies; 1581 participants; <a href="./references#CD004421-fig-00902" title="">Analysis 9.2</a>), with no heterogeneity (P = 0.87). </p> </section> </section> <section id="CD004421-sec4-0016"> <h5 class="title">Publication status</h5> <p>For a sensitivity analysis conducted to assess publication bias, studies with fully published efficacy papers were examined as a separate group from those published in non‐peer‐reviewed format only (i.e. abstracts or online theses). </p> <section id="CD004421-sec5-0024"> <h6 class="title">Overall survival</h6> <p>Twenty‐five studies (38,208 women) had a published efficacy paper (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>: <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>), and the HR of 0.88 favoured taxane‐containing treatment (95% CI 0.84 to 0.92; P &lt; 0.001; <a href="./references#CD004421-fig-01001" title="">Analysis 10.1</a>), with moderate heterogeneity (I² = 33%; P = 0.05). One study (972 women) ‐ <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a> ‐ had data available in an online thesis and indicated that the treatment effect persisted with an HR of 0.67, in favour of taxane‐containing treatment (95% CI 0.48 to 0.94; P = 0.05) (<a href="./references#CD004421-fig-01001" title="">Analysis 10.1</a>). </p> </section> <section id="CD004421-sec5-0025"> <h6 class="title">Disease‐free survival</h6> <p>Twenty‐seven studies with 28 treatment comparisons (40,310 women) included in this analysis had a published efficacy paper (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a>; <a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a>; <a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a>; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a>; <a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a>; <a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a>; <a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a>; <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>; <a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>), estimating the HR as 0.88, favouring the taxane‐containing group (95% CI 0.85 to 0.92; P &lt; 0.001; <a href="./references#CD004421-fig-01002" title="">Analysis 10.2</a>), with substantial heterogeneity (I² = 62%; P &lt; 0.001). Two studies (1599 women) had data available in abstracts or online theses (<a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a>; <a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a>), reporting an HR for DFS of 0.84 (95% CI 0.67 to 1.04; P = 0.10; <a href="./references#CD004421-fig-01002" title="">Analysis 10.2</a>), with no heterogeneity (P = 0.42). </p> <p>A funnel plot did not support any publication bias for the studies reviewed (<a href="#CD004421-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD004421-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Overall effect of taxanes, outcome: 1.1 Overall survival ‐ all studies." data-id="CD004421-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Overall effect of taxanes, outcome: 1.1 Overall survival ‐ all studies. </p> </div> </div> </div> </section> </section> </section> <section id="CD004421-sec3-0028"> <h4 class="title">Toxicity</h4> <p>Toxic effects of taxane therapy have been well characterised and were expected to be observed in the taxane‐containing arms. We noted heterogeneity between studies with the use of different control chemotherapies and varying doses and scheduling of the taxane drug. This heterogeneity needs to be considered on a trial‐by‐trial basis to interpret the tolerability of each taxane‐containing regimen. Toxicity data were extracted and combined for analysis. </p> <p>Of the 29 included studies, 28 provided extractable data on toxicity. No toxicity data could be extracted from <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a> studies. Data were extracted and analysed for febrile neutropenia, grade 3 or 4 neuropathy (sensory and motor), grade 3 or 4 fatigue, grade 3 or 4 stomatitis, cardiotoxicity, grade 3 or 4 nausea and/or vomiting, and secondary leukaemia or myelodysplasia. These outcomes are illustrated in Analysis 11 (<a href="./references#CD004421-fig-01101" title="">Analysis 11.1</a> to <a href="./references#CD004421-fig-01110" title="">Analysis 11.10</a>). Definitions of toxicity varied between studies, and the specific definitions from each study are reported in <a href="#CD004421-tbl-0015">Table 2</a>. When toxicity was reported as less than 1%, it was treated as 0% for the purposes of statistical comparison. It was not possible to determine the treated population (i.e. only those women receiving chemotherapy) in <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>. In this case, the randomised population was used for the denominator when the odds ratio was calculated. </p> <div class="table" id="CD004421-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Grouping of toxicity outcomes and description of individual study definitions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiotoxicity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Febrile neutropenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neuropathy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea/vomiting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stomatitis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiac symptoms: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neurological symptoms: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 mucositis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Congestive heart failure (cardiac function grade 3 or 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": Protocol definition ‐ fever of grade 2 or more concomitant with grade 4 neutropenia requiring IV antibiotics, hospitalisation, or both </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neurosensory effects: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 or severe vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 asthenia: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiac function toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": protocol defined grade 4 neutropenia, fever with &gt; 38 degrees Celsius, NCI CTC (version 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neurosensory effects: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 or severe vomiting: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher asthenia: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher stomatitis: NCI CTC (version 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiotoxicity: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 peripheral neuropathy: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: WHO toxicity criteria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher cardiotoxicity (left ventricular systolic dysfunction, restrictive cardiomyopathy, general cardiac, cardiac deaths attributed to protocol treatment ‐ myocardial infarction and left ventricular dysfunction) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as grade 3/4 febrile neutropenia: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy (reported both sensory and motor): NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Congestive heart failure during treatment or post treatment follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosed congestive cardiac failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 febrile neutropenia: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 peripheral neuropathy: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 congestive heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": toxicity criteria not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy (reported both sensory and motor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher vomiting: toxicity criteria not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher fatigue: toxicity criteria not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher stomatitis: toxicity criteria not specified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptomatic cardiac failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 neuropathy reported only: NCI CTC (no version provided)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 heart rhythm toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": NCT CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 mucositis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "neutropenic fever": NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy (reported both sensory and motor): NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiac dysfunction, Grade 4 cardiac ischaemia, Grade 3 arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 sensory neuropathy: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 mucositis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 arrhythmia, Grade 3/4 congestive heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": protocol defined fever Grade 2 or higher with Grade 4 neutropenia requiring intravenous antibiotics, hospitalisation, or both </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 peripheral neuropathy (reported both sensory and motor): NCI CTC (version 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" grade 3/4: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 peripheral sensory neuropathy: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and vomiting: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 mucositis: NCI CTC (version 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reversible cardiotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "neutropenic fever" grade 3/4: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neurotoxicity: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 mucositis: NCI CTC (version 3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiotoxicity: WHO criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" grade 3/4: WHO criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neurological toxicity: WHO criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and vomiting: WHO criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: WHO criteria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 peripheral neuropathy: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" grade 3/4: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neurotoxicity: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 asthenia: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 to 5 congestive heart failure and cardiac ischaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" grade 1 to 5: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 to 5 sensory neuropathy: NCI CTC version 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 to 5 vomiting: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 to 5 fatigue: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 to 5 mucositis, stomatitis, oesophagitis: NCI CTC (version 3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" grade 3/4: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy (reported both sensory and motor): NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" grade 3/4: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy (reported both sensory and motor): NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher cardiac dysfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any serious adverse cardiac event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: WHO toxicity criteria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" defined as any Grade 3/4 neutropenia plus fever (&gt; 38 degrees) requiring antibiotics: NCI CTC (version 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 mucositis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiac event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" Grade 3/4: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea‐vomiting: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: WHO toxicity criteria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" Grade 3/4: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 lethargy: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis (mucositis): NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac function toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy (reported both sensory and motor): NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 asthenia: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 peripheral neuropathy: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea (vomiting not reported): NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death due to cardiac event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" Grade 3/4 : NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 asthenia: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 1)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>NCI CTC: National Cancer Institute Common Toxicity Criteria<br/> NR: not reported<br/> WHO: World Health Organziation </p> </div> </div> <section id="CD004421-sec4-0017"> <h5 class="title">Febrile neutropenia</h5> <p>Twenty‐four studies with 25 treatment comparisons provided data on febrile neutropenia. Other myelosuppression toxicity data were reported in multiple studies (grade 3 to 4 neutropenia, grade 3 to 4 infection, and infection requiring antibiotics); however, febrile neutropenia was the most consistently reported outcome. Pooled analysis of these studies found that taxane‐containing regimens probably resulted in a small increase in risk of febrile neutropenia compared to non‐taxane‐containing regimens (OR 1.55, 95% CI 0.96 to 2.49; P = 0.07; 33,763 participants; 24 studies (25 treatment comparisons); moderate‐certainty evidence; <a href="./references#CD004421-fig-01101" title="">Analysis 11.1</a>; <a href="#CD004421-fig-0006">Figure 6</a>). The risk was highest for studies that administered the taxane concurrently with an anthracycline (OR 5.76, 95% CI 3.36 to 9.87; P &lt; 0.001; 8552 women; 6 studies; <a href="./references#CD004421-fig-01101" title="">Analysis 11.1</a>), with substantial heterogeneity (I² = 86%; P &lt; 0.001) rather than sequential taxane and anthracycline treatment (OR 1.31, 95% CI 0.82 to 2.10; P = 0.26; 20,148 women; 15 studies (16 treatment comparisons); <a href="./references#CD004421-fig-01101" title="">Analysis 11.1</a>), also with substantial heterogeneity (I² = 93%; P &lt; 0.001). There was little to no difference in the risk of febrile neutropenia among studies that compared a taxane replacement for an anthracycline versus control (OR 0.22, 95% CI 0.02 to 3.04; P = 0.26; 5063 women; 3 studies; <a href="./references#CD004421-fig-01101" title="">Analysis 11.1</a>), and heterogeneity was substantial (I² = 96%; P &lt; 0.001). The test for differences between subgroups was significant (P &lt; 0.001). </p> <div class="figure" id="CD004421-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 11 Toxicities, outcome: 11.1 Febrile neutropenia by sequential or concurrent anthracycline/taxane." data-id="CD004421-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 11 Toxicities, outcome: 11.1 Febrile neutropenia by sequential or concurrent anthracycline/taxane. </p> </div> </div> </div> <p>A subgroup analysis indicated that increased risk of febrile neutropenia for taxane‐containing regimens (compared to non‐taxane regimens) appeared to be driven by docetaxel rather than paclitaxel (<a href="./references#CD004421-fig-01102" title="">Analysis 11.2</a>). Docetaxel‐containing regimens were likely to increase the risk of febrile neutropenia compared to non‐taxane regimens (OR 2.83, 95% CI 1.88 to 4.27; P &lt; 0.001; 22,596 women; 16 studies; significant heterogeneity: I² = 92%; P &lt; 0.001; <a href="./references#CD004421-fig-01102" title="">Analysis 11.2</a>.1), and paclitaxel‐containing regimens were likely to reduce the risk of febrile neutropenia compared to non‐taxane regimens (OR 0.36, 95% CI 0.19 to 0.67; P &lt; 0.001; 11,558 women; 8 studies (9 treatment comparisons); substantial heterogeneity (I² = 88%; P &lt; 0.001). The test for differences between subgroups was significant (P &lt; 0.001). </p> </section> <section id="CD004421-sec4-0018"> <h5 class="title">Grade 3/4 neuropathy</h5> <p>Twenty‐two studies with 23 treatment comparisons reported grade 3 or 4 neuropathy. Of these, four studies provided data on neurosensory neuropathy only, six studies reported peripheral neuropathy only, seven studies reported sensory and motor neuropathy separately, and six reported neurotoxicity (no further specifics provided). Taxane‐containing regimens likely resulted in a large increase in neuropathy compared to controls (OR 6.89, 95% CI 3.23 to 14.71; P &lt; 0.001; 31,033 women; moderate‐certainty evidence; <a href="./references#CD004421-fig-01103" title="">Analysis 11.3</a>), with substantial heterogeneity (I² = 82%; P &lt; 0.001). </p> <p>A subgroup analysis suggested that the increase in risk of grade 3 or 4 neuropathy for taxane‐containing regimens compared to non‐taxane regimens tended to be worse for women receiving paclitaxel than docetaxel (<a href="./references#CD004421-fig-01104" title="">Analysis 11.4</a>); however the confidence intervals were very wide. For women receiving paclitaxel, the OR was 11.93 (95% CI 3.59 to 39.70; 10 studies (11 treatment comparisons); 12,678 women; substantial heterogeneity; I² = 85%; P &lt; 0.001; <a href="./references#CD004421-fig-01104" title="">Analysis 11.4</a>.2), and for docetaxel, the OR was 3.74 (95% CI 1.33 to 10.53; 11 studies, 18,355 women; substantial heterogeneity; I² = 79%; P &lt; 0.001; <a href="./references#CD004421-fig-01104" title="">Analysis 11.4</a>.1). The test for difference between subgroups was not statistically significant (P = 0.15). </p> </section> <section id="CD004421-sec4-0019"> <h5 class="title">Grade 3/4 fatigue</h5> <p>Sixteen studies were pooled for analysis of grade 3 or 4 fatigue. Taxane‐containing regimens likely increased the risk of fatigue compared to non‐taxane‐containing regimens (OR 1.81, 95% CI 1.31 to 2.49; P &lt; 0.001; 25,003 women; <a href="./references#CD004421-fig-01105" title="">Analysis 11.5</a>), with substantial heterogeneity (I<sup>2</sup> = 83%; P &lt; 0.001). </p> </section> <section id="CD004421-sec4-0020"> <h5 class="title">Grade 3/4 stomatitis</h5> <p>Twenty‐two studies with 23 treatment comparisons assessed grade 3 or 4 stomatitis. Pooled analysis of these studies revealed that taxane‐containing regimens likely resulted in little to no difference in stomatitis compared to controls (OR 1.29, 95% CI 0.93 to 1.78; P = 0.12; 22,648 women; <a href="./references#CD004421-fig-01106" title="">Analysis 11.6</a>), with substantial heterogeneity (I² = 81%; P &lt; 0.001). </p> <p>A subgroup analysis indicated that the docetaxel‐containing regimens were likely to increase the risk of stomatitis compared to control regimens (OR 1.73, 95% 1.28 to 2.35; 16 studies; 22648 participants), with substantial heterogeneity (I² = 73%; P &lt; 0.001), and paclitaxel‐containing regimens were likely to result in little to no difference in grade 3/4 stomatitis compared to control regimens (OR 0.64, 95% CI 0.31 to 1.32; 7 studies; 6852 participants), with substantial heterogeneity (I² = 81%; P &lt; 0.001). The test for difference between subgroups was significant (P = 0.01). </p> </section> <section id="CD004421-sec4-0021"> <h5 class="title">Cardiotoxicity</h5> <p>Twenty‐three studies provided extractable data on cardiotoxicity. Pooled analysis of these studies indicated that administering taxane‐containing regimens probably resulted in little to no difference in cardiotoxicity compared to non‐taxane‐containing regimens (OR 0.87, 95% CI 0.56 to 1.33; 32,894 participants; 23 studies; moderate‐quality evidence; <a href="./references#CD004421-fig-01107" title="">Analysis 11.7</a>). When the same planned dose of anthracycline was used in the taxane‐containing arm and in the control arm, there was no difference in the risk of cardiotoxicity between groups (HR 1.27, 95% CI 0.88 to 1.84; 14,967 women; 9 studies; <a href="./references#CD004421-fig-01107" title="">Analysis 11.7</a>), with little heterogeneity (I² = 24%; P = 0.24). Risk of cardiotoxicity was reduced in studies that provided a lower planned dose of anthracycline in the taxane arm than in the control arm (OR 0.39, 95% CI 0.18 to 0.86; 12,473 women; 10 studies; <a href="./references#CD004421-fig-01107" title="">Analysis 11.7</a>), with little heterogeneity (I² = 24%; P = 0.22). Four studies were designed with the taxane replacing the anthracycline and showed little to no difference in cardiotoxicity between treatment groups (OR 1.01, 95% CI 0.26 to 3.91; 5454 women; 4 studies; <a href="./references#CD004421-fig-01107" title="">Analysis 11.7</a>), with moderate heterogeneity (I² = 58%; P = 0.07). The test for differences between subgroups was significant (P = 0.03). </p> </section> <section id="CD004421-sec4-0022"> <h5 class="title">Grade 3/4 nausea and/or vomiting</h5> <p>Twenty‐five studies with 26 treatment comparisons were pooled for analysis of grade 3 or 4 nausea and/or vomiting. If studies did not report nausea/vomiting, we included data related to vomiting only if reported (refer to <a href="#CD004421-tbl-0015">Table 2</a>). Administration of taxane‐containing regimens likely resulted in little to no difference in nausea/vomiting compared to non‐taxane‐containing regimens (OR 0.83, 95% CI 0.67 to 1.04; 34,450 women; moderate‐certainty evidence; <a href="./references#CD004421-fig-01108" title="">Analysis 11.8</a>), with substantial heterogeneity (I² = 77%; P &lt; 0.001). </p> </section> <section id="CD004421-sec4-0023"> <h5 class="title">Secondary leukaemia or myelodysplasia</h5> <p>A total of 86 cases of secondary leukaemia or myelodysplasia were reported from 18 studies, with 19 treatment comparisons: 39 cases from taxane‐containing regimens and 47 from control regimens. There was little to no difference in the risk of developing secondary leukaemia or myelodysplasia between groups (OR 0.85, 95% CI 0.54 to 1.33; 33,225 women; <a href="./references#CD004421-fig-01109" title="">Analysis 11.9</a>), with no heterogeneity (P = 0.62). </p> <p>Two studies reported on the development of other second malignancies. In <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>, 14 women in the taxane‐containing arm and 20 women in the control arm developed a second cancer, and in <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>, this occurred in five women from the taxane‐containing arm and in four women from the control arm. </p> </section> <section id="CD004421-sec4-0024"> <h5 class="title">Treatment‐related death</h5> <p>Treatment‐related death was uncommon for both taxane‐containing and non‐taxane‐containing groups. Treatment‐related deaths were defined in the trials as "toxic death", "treatment‐related death", and "death occurring during treatment or within 30 days post‐treatment". In all, 68 treatment‐related deaths were recorded from 22 studies during chemotherapy: 35 from taxane‐containing regimens and 33 from control regimens. Administering taxane‐containing regimens resulted in little to no difference in treatment‐related deaths compared to non‐taxane‐containing regimens (OR 1.24, 95% CI 0.63 to 2.47; 34,882 women; 22 studies; <a href="./references#CD004421-fig-01110" title="">Analysis 11.10</a>), with little heterogeneity (I² = 26%, P = 0.17). One trial reported deaths without describing the causes (three women; <a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a>). Several studies reported additional deaths but excluded these as they were not considered related to treatment. </p> <p>For the purposes of this review, we have focused on the aforementioned toxicities commonly reported across most trials. Other reported toxicities ranged from grade 3/4 myalgia or arthralgia, anaemia, allergy, or oedema, to neurotoxicity, but reporting on the frequency of all of these toxicities was beyond the remit of this review. </p> </section> </section> <section id="CD004421-sec3-0029"> <h4 class="title">Quality of life</h4> <p>Seven studies reported low‐certainty evidence for quality of life (QoL) (<a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>; <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a>; <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a>; <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>; <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a>; <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a>; <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a>); details of these findings are summarised in <a href="#CD004421-tbl-0016">Table 3</a>. NCIC‐CTG MA21 ‐ <a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> and <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a> ‐ stated that QoL data would be reported in a separate article. <a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a> demonstrated a transient reduction in both treatment arms; the reduction in QoL score was greater in the taxane‐containing regimen, but by first follow‐up, both treatment arms had returned to baseline. Similarly, in <a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a>, both groups had decreased scores on the EORTC questionnaire used to assess quality of life in cancer patients (EORTC‐C30), and changes in scores on the breast cancer‐specific EORTC QoL questionnaire (EORTC BR23) over time were similar in the two groups. <a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a> and <a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a> did not report any differences in QoL scores between treatment arms either at the beginning or at the end of chemotherapy. <a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a> reported no differences in global QoL scores, functioning scales, and other items; however, there was worsening of systemic therapy side effects in the docetaxel group compared to the CMF group at the end of one or more cycles (<a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a>). <a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a> reported decreased QoL in the taxane‐containing group compared to the control group, but this was resolved by week 44, and there were no significant differences between groups during the follow‐up period. <a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a> noted a reduction in QoL global, physical, emotional functioning, social functioning, and fatigue scores compared to the control group; more nausea and vomiting was reported in the control group than in the taxane‐containing group. </p> <div class="table" id="CD004421-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Quality of life</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Instruments used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary of findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 and the breast cancer‐specific QLQ‐BR23 at baseline, before each course of chemotherapy, and at 4 weeks, 6 weeks, and 6 months after completion of chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both treatment groups had decreased EORTC‐C30 scores for physical, role, emotional, social, and cognitive functioning from baseline to 28 days after chemotherapy. Global health scores also decreased in this time frame for both groups. Changes in symptom scores were generally similar between treatment groups with the exception of nausea/vomiting and pain scores. Nausea/vomiting was worse for the FEC120 group than for the EC‐Doc group (+9.42 above baseline vs +1.88), and pain scores were worse in the EC‐Doc group (+9.18 for EC‐Doc vs ‐1.61 for FEC120). Changes in items on the EORTC BR23 over time were quantitatively and qualitatively similar in the 2 treatment groups </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 (version 2.0) and the breast cancer‐specific QLQ‐BR23 (version 1.0) questionnaires at baseline, before cycles 3 and 5, at 3 to 4 weeks after completion, and at 6, 12, and 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both FAC and TAC arms led to a transient and statistically significant reduction in QoL scores, which returned to baseline levels at first follow‐up visit. QoL measures were similar between groups and were similar to baseline measures at 6 months and at the end of 2 years </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QoL results designed to study short‐ and long‐term toxicities on quality of life by treatment agent and duration. No further details provided </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QoL to be reported in a companion study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 and the breast cancer‐specific QLQ‐BR23 in the clinic at baseline and 9 months, 2 years, and 5 years after random assignment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in overall QoL or across any of the scales between treatments at 9 months, 2 years, or 5 years </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 and the breast cancer‐specific QLQ BR23 at baseline, and at the end of the first, second, and third cycles of chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference reported for QoL global functioning scales and other items. However there was worsening of systemic therapy side effects, future perspective, nausea and vomiting, diarrhoea, appetite loss, and upset by hair loss and body experience with docetaxel compared to CMF at the end of 1 or more cycles </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 and the breast cancer‐specific QLQ‐BR23 at baseline after each chemotherapy cycle and at 6, 12, and 24 months after completion of chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During chemotherapy, QoL decreased and was worse with TAC than with FAC, but this effect resolved by week 44. There were no statistically significant differences in QoL between TAC+G‐CSF and FAC after cycle 6 or during further follow‐up </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial registry record indicates that QoL will be compared across treatment arms. No further details provided </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QoL information not yet reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 questionnaire at baseline and on completion of chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 23% of participants (72 participants in E‐T‐CMF and 67 participants in E‐CMF) completed baseline and end of chemotherapy questionnaires. There was no difference between the 2 treatment arms at the beginning or at the end of chemotherapy. Significant increase in nausea and vomiting for both groups. Social functioning significantly decreased in the taxane‐containing arm, and emotional functioning and pain significantly improved in the control arm </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCIC‐CTGMA21 (<a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a>; <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 and the breast cancer‐specific QLQ‐BR within 7 days before random assignment and afterwards </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QoL results will be reported in a separate article</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selected centres invited participants to quality of life substudy. These patients completed EORTC QLQ‐C30, QLQ‐BR23, and Hospital Anxiety and Depression Scale (HADS) before randomisation, before fifth and after eighth cycles, and at 9, 12, 18, and 24 months post chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEC‐D was associated with worse global QoL (P = 0.001), physical (P &lt; 0.0001), role (P = 0.002), emotional functioning (P = 0.008), social functioning (P = 0.003), pain (P = 0.001), and fatigue (P = 0.006) compared to control. In contrast, there was more nausea and vomiting in the control group (P = 0.01) than in the FEC‐D group </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CMF: cyclophosphamide, methotrexate and fluorouracil<br/> E‐CMF: epirubicin‐ cyclophosphamide, methotrexate and fluorouracil<br/> EC‐Doc: epirubicin, cyclophosphamide‐docetaxel<br/> EORTC QLQ‐C30: European Organisation for Research and Treatment of Cancer (EORTC) core Quality of Life Questionnaire C30 (QLQ‐C30)<br/> QLQ‐BR23: breast cancer‐specific Quality of Life Questionnaire BR23<br/> E‐T‐CMF: epirubicin‐paclitaxel‐cyclophosphamide, methotrexate, fluorouracil<br/> FAC: fluorouracil, doxorubicin, cyclophosphamide<br/> FEC‐D: fluorouracil, epirubicin, cyclophosphamide ‐ docetaxel<br/> TAC: docetaxel, doxorubicin, cyclophosphamide </p> </div> </div> </section> <section id="CD004421-sec3-0030"> <h4 class="title">Cost‐effectiveness</h4> <p>One study presented data on cost‐effectiveness, finding that the extra cost of anthracycline plus docetaxel treatment compared to anthracycline alone was offset by the lower rate of recurrence in the anthracycline plus docetaxel group (<a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>). The cost per quality‐adjusted life‐year (QALY) gained by adding the taxane was reported to be €2372 (upper CI €55,515). This value was reported to be a cost‐effective alternative. </p> <section id="CD004421-sec4-0025"> <h5 class="title">Sensitivity analysis</h5> <section id="CD004421-sec5-0026"> <h6 class="title">Low versus high or unclear risk of bias</h6> <p>Post‐hoc subgroup analyses were conducted to investigate treatment effects in studies with low risk of bias compared to studies with unclear/high risk of bias. Of the 29 studies, 23 studies (24 treatment comparisons) were considered to be at low risk overall. Six studies were grouped as having unclear or high risk of bias overall (<a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a>; <a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a>; <a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a>; <a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a>; <a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a>; <a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a>). </p> <section id="CD004421-sec6-0001"> <p><b>Overall survival</b></p> <p>Analysis of low risk of bias studies demonstrated an HR of 0.90, favouring the taxane‐containing group (95% CI 0.86 to 0.95; P &lt; 0.001; <a href="./references#CD004421-fig-01201" title="">Analysis 12.1</a>), with moderate heterogeneity (I² = 28%; P = 0.12). For the six studies categorised as having unclear or high risk of bias, the HR favoured taxane‐containing regimens (HR 0.74, 95 CI 0.65 to 0.83; P &lt; 0.001; <a href="./references#CD004421-fig-01201" title="">Analysis 12.1</a>), with no heterogeneity (P = 0.68). </p> </section> <section id="CD004421-sec6-0002"> <p><b>Disease‐free survival</b></p> <p>Twenty‐three low risk of bias studies (24 treatment comparisons) had data available for this outcome and showed an HR of 0.90 in favour of taxane‐containing regimens (95% CI 0.87 to 0.94; P &lt; 0.001; 35,935 women; <a href="./references#CD004421-fig-01202" title="">Analysis 12.2</a>). Heterogeneity was moderate (I² = 57%; P &lt; 0.001). For the six studies judged as having unclear or high risk of bias, an HR of 0.76 favoured taxane‐containing regimens (95% CI 0.69 to 0.84; P &lt; 0.001; 5974 women), with moderate heterogeneity (I² = 42%; P = 0.12). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004421-sec1-0006" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004421-sec1-0006">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004421-sec1-0023">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004421-sec1-0006"></div> <section id="CD004421-sec2-0011"> <h3 class="title" id="CD004421-sec2-0011">Summary of main results</h3> <p>This review update provides high‐quality evidence supporting the conclusion that use of a taxane drug as part of the adjuvant chemotherapy regimen following surgery for early‐stage breast cancer in women with moderate to high risk of recurrence leads to improvement in overall survival (OS) and disease‐free survival (DFS) (see <a href="./full#CD004421-tbl-0001">summary of findings Table for the main comparison</a>). Among these women, the hazard ratio for OS was 0.87, and for DFS 0.88, favouring use of a taxane as part of the adjuvant chemotherapy regimen when compared to adjuvant regimens that did not contain a taxane. </p> <p>This review included 29 studies (totaling 41,911 randomised women, 6501 deaths, and 10,271 DFS events), which is an adequate number to establish conclusive results. With the addition of 17 new studies and updated follow‐up data from previously included studies, little evidence suggests that the hazard ratio will change over time. We identified three ongoing studies, and there may be further unpublished studies that have not been identified for this review update. It is possible that publication bias in favour of significant findings may have led to an overestimation of the overall treatment effect; however, the funnel plot does not support this. </p> <p>Overall, taxane‐containing regimens were well tolerated but increased the risk of some adverse events. Moderate‐quality evidence shows that there was a difference in toxicity between taxane‐containing regimens and non‐taxane‐containing regimens. This is not unexpected based on established toxicity profiles for the taxane drugs. A small increase in rates of febrile neutropenia, neuropathy, and fatigue was evident for the taxane‐containing regimens. Researchers have noted no significant differences in the risk of developing cardiotoxicity, stomatitis, nausea and/or vomiting, secondary haematological or other second cancers, nor treatment‐related death. Less cardiotoxicity was seen with taxane‐containing regimens that employed less anthracycline than was seen with the control intervention. Seven studies reported quality of life (QoL) results. Overall, low‐quality evidence suggests no differences in QoL between groups during follow‐up. </p> <p>The subgroup analysis looked at the relative efficacy for each type of taxane. For docetaxel and paclitaxel, the hazard ratio for OS was 0.86 (range 0.81 to 0.92) and 0.89 (range 0.82 to 0.96), respectively; and for DFS the hazard ratio was 0.87 (range 0.82 to 0.91) and 0.91 (range 0.85 to 0.96), respectively. No conclusions can be drawn about the relative efficacy of the two agents without a direct comparison. Such direct comparisons are underway, and some results have been published. </p> </section> <section id="CD004421-sec2-0012"> <h3 class="title" id="CD004421-sec2-0012">Overall completeness and applicability of evidence</h3> <p>This review provides preliminary evidence for restricting adjuvant taxane chemotherapy to lymph node‐positive women and shows that efficacy appeared equivalent in trials that included both node‐positive and node‐negative groups and only node‐negative groups. The absolute recurrence risk for an individual patient must be considered when one is making clinical decisions on the use of a taxane‐containing adjuvant chemotherapy regimen. Limited evidence suggests that taxane chemotherapy restricted to women with hormone receptor‐positive breast cancer could provide additional benefit in terms of survival, but for disease‐free survival, efficacy in trials of hormone receptor‐positive and hormone receptor‐negative groups is unclear. Further questions that are beyond the scope of this review include efficacy in women with more than four involved axillary lymph nodes and the role of human epidermal growth factor receptor 2 (HER2) in breast cancer treatment. </p> </section> <section id="CD004421-sec2-0013"> <h3 class="title" id="CD004421-sec2-0013">Quality of the evidence</h3> <p>This updated review contains 29 included studies involving over 41,000 women. High‐quality evidence supports the use of taxane‐containing regimens in the adjuvant setting with an increase in survival time and in time free of disease recurrence. Some clinical heterogeneity between studies was evident, with variation in choice of control chemotherapy, doses, and treatment scheduling. Post‐hoc analyses in a side‐by‐side comparison of pooled data were performed for several subgroups. Benefit appears to be no less when the taxane is substituted for part of the control regimen as opposed to adding it to the control regimen. This is also the case when taxane regimens of the same duration are compared with regimens of longer duration than the control regimen, when three cycles of taxane treatment rather than four or more are compared, and when sequential anthracycline and taxane combination is given rather than concurrent administration. </p> </section> <section id="CD004421-sec2-0014"> <h3 class="title" id="CD004421-sec2-0014">Potential biases in the review process</h3> <p>For the review update, trialists were contacted if data were not fully reported in the full‐text article or if no information aside from a conference proceeding abstract was available. We tested whether publication status (i.e. full text vs non‐peer‐reviewed information) had an impact on the effect estimate. It was reassuring that benefit from taxanes in the adjuvant setting persisted when data for overall survival were analysed; however, this benefit was not sustained for disease‐free survival, with data from abstracts, unpublished manuscripts, or online theses (related to four studies) showing no added benefit from taxanes compared to control interventions. </p> </section> <section id="CD004421-sec2-0015"> <h3 class="title" id="CD004421-sec2-0015">Agreements and disagreements with other studies or reviews</h3> <p>Results of this meta‐analysis are in accordance with the findings of previous meta‐analyses (<a href="./references#CD004421-bbs2-0054" title="BriaE , NisticoC , CupponeF , CarliniP , CiccareseM , MilellaM , et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer2006;106(11):2337‐44. ">Bria 2006</a>; <a href="./references#CD004421-bbs2-0065" title="QinYY , LiH , GuoKJ , YeXF , WeiX , ZhouYH , et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta‐analysis of 19 randomized trials with 30698 patients. PLoS ONE2011;6(11):e26946. ">Qin 2011</a>). The <a href="./references#CD004421-bbs2-0054" title="BriaE , NisticoC , CupponeF , CarliniP , CiccareseM , MilellaM , et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer2006;106(11):2337‐44. ">Bria 2006</a> meta‐analysis included nine studies with 15,598 and 15,074 women analysed for DFS and OS, respectively. <a href="./references#CD004421-bbs2-0054" title="BriaE , NisticoC , CupponeF , CarliniP , CiccareseM , MilellaM , et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer2006;106(11):2337‐44. ">Bria 2006</a> reported the risk ratios for DFS and OS as 0.86 (95% CI 0.81 to 0.90) and 0.87 (95% CI 0.81 to 0.93), in favour of the taxane‐containing treatment group (<a href="./references#CD004421-bbs2-0054" title="BriaE , NisticoC , CupponeF , CarliniP , CiccareseM , MilellaM , et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer2006;106(11):2337‐44. ">Bria 2006</a>). The meta‐analysis by Bria et al included the <a href="./references#CD004421-bbs2-0037" title="BuzdarAU , SingletarySE , ValeroV , BooserDJ , IbrahimNK , RahmanZ , et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clinical Cancer Research2002;8(5):1073‐9. ">MD Anderson CC</a> trial, which was excluded from this Cochrane Review as published efficacy data did not distinguish results for adjuvant patients from those for neoadjuvant patients. Nineteen additional trials were included in the Cochrane Review, which provides even stronger supporting evidence for the efficacy of taxane‐containing regimens. Similarly, <a href="./references#CD004421-bbs2-0065" title="QinYY , LiH , GuoKJ , YeXF , WeiX , ZhouYH , et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta‐analysis of 19 randomized trials with 30698 patients. PLoS ONE2011;6(11):e26946. ">Qin 2011</a> reported a reduction in the number of deaths and in risk of disease recurrence for women receiving adjuvant taxane‐containing chemotherapy compared to those given chemotherapy without taxanes, and reported similar toxicity profiles as we have provided in our updated Cochrane Review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004421-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Review update: study flow diagram." data-id="CD004421-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Review update: study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004421-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Overall effect of taxanes, outcome: 1.1 Overall survival ‐ all studies." data-id="CD004421-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Overall effect of taxanes, outcome: 1.1 Overall survival ‐ all studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Overall effect of taxanes, outcome: 1.2 Disease‐free survival: all studies." data-id="CD004421-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Overall effect of taxanes, outcome: 1.2 Disease‐free survival: all studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Overall effect of taxanes, outcome: 1.1 Overall survival ‐ all studies." data-id="CD004421-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Overall effect of taxanes, outcome: 1.1 Overall survival ‐ all studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 11 Toxicities, outcome: 11.1 Febrile neutropenia by sequential or concurrent anthracycline/taxane." data-id="CD004421-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 11 Toxicities, outcome: 11.1 Febrile neutropenia by sequential or concurrent anthracycline/taxane. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall effect of taxanes, Outcome 1 Overall survival ‐ all studies." data-id="CD004421-fig-00101" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Overall effect of taxanes, Outcome 1 Overall survival ‐ all studies.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall effect of taxanes, Outcome 2 Disease‐free survival: all studies." data-id="CD004421-fig-00102" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Overall effect of taxanes, Outcome 2 Disease‐free survival: all studies.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall effect of taxanes, Outcome 3 Disease‐free survival: as defined in Cochrane protocol." data-id="CD004421-fig-00103" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Overall effect of taxanes, Outcome 3 Disease‐free survival: as defined in Cochrane protocol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Type of taxane, Outcome 1 Overall survival." data-id="CD004421-fig-00201" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Type of taxane, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Type of taxane, Outcome 2 Disease‐free survival." data-id="CD004421-fig-00202" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Type of taxane, Outcome 2 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00301"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Weekly or three‐weekly paclitaxel, Outcome 1 Overall survival." data-id="CD004421-fig-00301" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Weekly or three‐weekly paclitaxel, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00301">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00302"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Weekly or three‐weekly paclitaxel, Outcome 2 Disease‐free survival." data-id="CD004421-fig-00302" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Weekly or three‐weekly paclitaxel, Outcome 2 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00302">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00401"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sequential or concurrent anthracycline/taxane, Outcome 1 Overall survival." data-id="CD004421-fig-00401" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Sequential or concurrent anthracycline/taxane, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00401">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00402"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sequential or concurrent anthracycline/taxane, Outcome 2 Disease‐free survival." data-id="CD004421-fig-00402" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Sequential or concurrent anthracycline/taxane, Outcome 2 Disease‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00402">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00501"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Addition or substitution of taxane, Outcome 1 Overall survival." data-id="CD004421-fig-00501" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Addition or substitution of taxane, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00501">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00502"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Addition or substitution of taxane, Outcome 2 Disease‐free survival." data-id="CD004421-fig-00502" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Addition or substitution of taxane, Outcome 2 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00502">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00601"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Duration of chemotherapy, Outcome 1 Overall survival." data-id="CD004421-fig-00601" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Duration of chemotherapy, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00601">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00602"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Duration of chemotherapy, Outcome 2 Disease‐free survival." data-id="CD004421-fig-00602" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Duration of chemotherapy, Outcome 2 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00602">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00701"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Number of cycles of taxane‐containing chemotherapy, Outcome 1 Overall survival." data-id="CD004421-fig-00701" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Number of cycles of taxane‐containing chemotherapy, Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00701">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00702"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Number of cycles of taxane‐containing chemotherapy, Outcome 2 Disease‐free survival." data-id="CD004421-fig-00702" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Number of cycles of taxane‐containing chemotherapy, Outcome 2 Disease‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00702">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00801"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Lymph node status, Outcome 1 Overall survival." data-id="CD004421-fig-00801" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Lymph node status, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00801">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00802"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Lymph node status, Outcome 2 Disease‐free survival." data-id="CD004421-fig-00802" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Lymph node status, Outcome 2 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00802">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00901"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Hormone receptor status, Outcome 1 Overall survival." data-id="CD004421-fig-00901" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Hormone receptor status, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00901">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-00902"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Hormone receptor status, Outcome 2 Disease‐free survival." data-id="CD004421-fig-00902" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Hormone receptor status, Outcome 2 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-00902">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Publication status, Outcome 1 Overall survival." data-id="CD004421-fig-01001" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Publication status, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Publication status, Outcome 2 Disease‐free survival." data-id="CD004421-fig-01002" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Publication status, Outcome 2 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-011-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Toxicities, Outcome 1 Febrile neutropenia by sequential or concurrent anthracycline/taxane." data-id="CD004421-fig-01101" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Toxicities, Outcome 1 Febrile neutropenia by sequential or concurrent anthracycline/taxane. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Toxicities, Outcome 2 Febrile neutropenia by type of taxane." data-id="CD004421-fig-01102" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Toxicities, Outcome 2 Febrile neutropenia by type of taxane.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Toxicities, Outcome 3 Neuropathy (grade 3/4)." data-id="CD004421-fig-01103" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Toxicities, Outcome 3 Neuropathy (grade 3/4).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Toxicities, Outcome 4 Neuropathy (grade 3/4) by type of taxane." data-id="CD004421-fig-01104" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Toxicities, Outcome 4 Neuropathy (grade 3/4) by type of taxane.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Toxicities, Outcome 5 Fatigue (grade 3/4)." data-id="CD004421-fig-01105" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 Toxicities, Outcome 5 Fatigue (grade 3/4).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-011-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-011-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Toxicities, Outcome 6 Stomatitis (grade 3/4)." data-id="CD004421-fig-01106" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11 Toxicities, Outcome 6 Stomatitis (grade 3/4).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-011-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-011-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Toxicities, Outcome 7 Cardiotoxicity (includes grade 3/4 and symptomatic CCF)." data-id="CD004421-fig-01107" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11 Toxicities, Outcome 7 Cardiotoxicity (includes grade 3/4 and symptomatic CCF). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-011-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-011-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Toxicities, Outcome 8 Nausea and/or vomiting (grade 3/4)." data-id="CD004421-fig-01108" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.8</div> <div class="figure-caption"> <p>Comparison 11 Toxicities, Outcome 8 Nausea and/or vomiting (grade 3/4).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-011-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-011-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Toxicities, Outcome 9 Secondary leukaemia/myelodysplasia." data-id="CD004421-fig-01109" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.9</div> <div class="figure-caption"> <p>Comparison 11 Toxicities, Outcome 9 Secondary leukaemia/myelodysplasia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-011-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-011-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Toxicities, Outcome 10 Treatment‐related deaths." data-id="CD004421-fig-01110" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.10</div> <div class="figure-caption"> <p>Comparison 11 Toxicities, Outcome 10 Treatment‐related deaths.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-011-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Risk of Bias, Outcome 1 Overall survival." data-id="CD004421-fig-01201" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Risk of Bias, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004421-fig-01202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/urn:x-wiley:14651858:media:CD004421:CD004421-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_t/tCD004421-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Risk of Bias, Outcome 2 Disease‐free survival." data-id="CD004421-fig-01202" src="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Risk of Bias, Outcome 2 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-fig-01202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/media/CDSR/CD004421/image_n/nCD004421-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004421-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Taxane‐containing chemotherapy vs any chemotherapy without taxane for early breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Taxane‐containing chemotherapy compared to any chemotherapy without taxane for early breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with early breast cancer (operable, stages I to IIIA)<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> taxane‐containing chemotherapy<br/> <b>Comparison:</b> any chemotherapy without taxanes </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any chemotherapy without taxanes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with taxane‐containing chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Overall survival<br/> Follow‐up: range 5 years to 10 years<br/> <br/> (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk of death</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.87<br/> (0.83 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>39,180<br/> (27 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Additional analyses (including specific taxane, scheduling, treatment duration, doses, node positive, and risk of bias) showed equivalent efficacy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000*</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b><br/> (67 to 73) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High risk of death</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000*</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b><br/> (169 to 184) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Disease‐free progression<br/> Follow‐up: range 4 years to 10 years<br/> <br/> (*baseline risks for low‐ and high‐risk groups in the control arm were estimated at 5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk of recurrence</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>HR 0.88<br/> (0.85 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>41,909<br/> (29 studies, 30 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>As above for overall survival</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 per 1000*</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b><br/> (120 to 130) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High risk of recurrence</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000*</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b><br/> (280 to 299) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/> Follow‐up: 1 to 62 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not estimable. In general, there did not seem to be differences in quality of life scores between groups at long‐term follow‐up </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(7 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies used the validated EORTC‐C30 questionnaire and measures were patient‐reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Febrile neutropenia<br/> Follow‐up: 3 to 7 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.43<br/> (0.89 to 2.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34,154<br/> (23 studies, 24 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There was a higher incidence of febrile neutropenia with docetaxel‐containing regimens</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b><br/> (50 to 120) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neuropathy (including grade 3/4 sensory or motor neuropathy, or both)<br/> Follow‐up: 3 to 7 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 6.89 (3.23 to 14.71)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31,033<br/> (22 studies, 23 comparisons) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A test for subgroup differences by taxane type was not significant</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1,000</b><br/> (18 to 76) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiotoxicity (including grade 3/4 and congestive cardiac failure)<br/> Follow‐up: 3 to 10 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.87<br/> (0.56 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>32,894<br/> (23 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risk of cardiotoxicity was reduced with lower planned dose of anthracycline</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/> (5 to 12) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; HR: hazard ratio; OR: odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Heterogeneity was detected (I² = 59%) mainly due to variations in chemotherapy backbones. The quality of evidence was not downgraded as variations in chemotherapy are likely to occur in clinical practice.<br/> <sup>b</sup>This outcome was downgraded because all measures were patient‐reported, taking place in open‐label studies, and therefore at high risk of bias. Although all studies used the validated EORTC‐C30 questionnaires, the time frames when women were given the questionnaires was variable, and lengths of follow‐up were different. In one study, only 23% of participants completed baseline and end of chemotherapy questionnaires.<br/> <sup>c</sup>There was significant heterogeneity across studies (I² = 96% for febrile neutropenia; I² = 82% for neuropathy).<br/> <sup>d</sup>The confidence interval crosses the line of no effect and does not rule out a small increase in toxicity from taxanes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Taxane‐containing chemotherapy vs any chemotherapy without taxane for early breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004421-tbl-0014"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Definition of "disease‐free survival"</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revised to iDFS (in 2016) in line with Standardized Definitions for Efficacy End Points (STEEP), where DFS referred to all invasive ipsilateral, regional, contralateral, and distant disease recurrences, second primary tumours, and death from any cause as events, and all non‐invasive in situ cancer events were excluded </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation to date of clinical relapse (histological or radiological evidence), a second cancer (except skin cancer other than melanoma or carcinoma in situ of breast or cervix), or death </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation until first date of local, regional, or distant relapse; diagnosis of a second primary cancer, including contralateral invasive breast cancer; or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from date of random assignment to date of locoregional and/or distant release</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from <i>study entry</i> until local recurrence, distant relapse, or death without relapse, whichever occurred first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation to date of first locoregional recurrence, first distant metastasis, or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from date of randomisation to locoregional recurrence, distant recurrence, new primary breast cancer, or death </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Freedom from progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported in trial publication</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interval between randomisation and locoregional or distant relapse or contralateral invasive breast cancer or second primary invasive non‐breast cancer or ipsilateral or contralateral in situ ductal carcinoma or death without cancer, whichever occurred first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from date of random assignment to date of invasive breast cancer recurrence, invasive contralateral breast cancer, or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrence‐free survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation to date of detection of local or distant relapse (histological or radiological evidence) or contralateral invasive breast cancer or death without recurrence </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from random assignment to date of local, regional, or metastatic relapse; date of a second primary malignancy; or death form any cause, whichever occurred first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from date of randomisation to date of local, regional, or metastatic relapse; diagnosis of second primary cancer or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>According to the definition of invasive disease‐free survival (IDFS) in the STEEP system </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation to first relapse (local, regional, distant), contralateral breast cancer, or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from date of randomisation to date of local recurrence, distant metastases, contralateral breast cancer, second primary malignancy, or death from any cause, whichever occurred first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation until local recurrence, distant relapse, or death (without relapse) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation to date of breast cancer recurrence (local, regional, or distant), invasive contralateral breast cancer, non‐breast second primary cancer, or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>iDFS and DDFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any local invasive or distant recurrence of breast cancer, any contralateral breast cancer, any second malignancy, and any death irrespective of its cause for iDFS </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from random assignment to time of recurrence of the primary breast cancer (local, nodal, metastatic). Patients with contralateral breast cancer, second malignancy, non‐disease‐related death were censored </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from random assignment to time of recurrence of the primary breast cancer (local, nodal, metastatic). Patients with contralateral breast cancer, second malignancy, non‐disease‐related death were censored </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation until local, regional, or distant treatment failure, contralateral breast cancer, non‐breast second primary cancer, or death </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation until first relapse (local, regional, or distant), contralateral breast cancer, or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TTR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to locoregional relapse, contralateral breast cancer, or distant metastasis, whichever occurs first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0025" title="RoyC , ChoudhuryKB , PalM , SahaA , BagS , BanerjeeC . Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of paclitaxel in node‐positive breast cancer. Indian Journal of Cancer2012;49(3):266‐71. ">Roy</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from <i>study entry</i> to first local recurrence or distant metastasis, or death as a result of any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation until first relapse (locoregional or distant), contralateral breast cancer, or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from randomisation to first invasive relapse, new primary breast cancer (ipsilateral or contralateral), or death form any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from date of randomisation to local or distant recurrence or contralateral breast cancer or second primary malignancy or death from any case, whichever occurred first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time between randomisation and date of first documented disease recurrence or death from any cause </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time from <i>first dose of chemotherapy</i> until date of any recurrence of breast cancer, a new second breast cancer or any other type of cancer, death due to any cause without relapse or recurrence of breast cancer, or date of last patient contact </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>DFS: disease‐free survival<br/> EFS: event‐free survival<br/> RFS: relapse‐free survival<br/> TTR: time to recurrence </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Definition of "disease‐free survival"</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004421-tbl-0015"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Grouping of toxicity outcomes and description of individual study definitions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiotoxicity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Febrile neutropenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neuropathy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea/vomiting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fatigue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stomatitis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiac symptoms: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neurological symptoms: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 mucositis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Congestive heart failure (cardiac function grade 3 or 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": Protocol definition ‐ fever of grade 2 or more concomitant with grade 4 neutropenia requiring IV antibiotics, hospitalisation, or both </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neurosensory effects: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 or severe vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 asthenia: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0003" title="CrownJP , FrancisP , DiLeoA . Docetaxel given concurrently with or sequentially to anthracycline‐based adjuvant therapy for patients with node‐positive breast cancer, in comparison with non‐taxane combination chemotherapy: first results of the BIG 2‐98 trial at 5 years median follow‐up. Journal of Clinical Oncology2006;24(Suppl 18):LBA519. FrancisP , CrownJ , DiLeoA , BuyseM , BalilA , AnderssonM , et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02‐98 randomized trial. Journal of the National Cancer Institute2008;100(2):121‐33. SonnenblickA , FrancisPA , Azim JrHA , deAzambujaE , NordenskjöldB , GutiérezJ , et al. Final 10‐year results of the Breast International Group 2‐98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer2015;51(12):1481‐9. ">BIG 2‐98</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiac function toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": protocol defined grade 4 neutropenia, fever with &gt; 38 degrees Celsius, NCI CTC (version 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neurosensory effects: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 or severe vomiting: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher asthenia: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher stomatitis: NCI CTC (version 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0004" title="BoccardoF , AmadoriD , GuglielminiP , SismondiP , FarrisA , AgostaraB , et al. Epirubicin followed by cyclophosphamide, methotrexate and 5‐fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high‐risk operable breast cancer. Oncology (United States)2010;78(3‐4):274‐81. ">Boccardo</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiotoxicity: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 peripheral neuropathy: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: WHO toxicity criteria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher cardiotoxicity (left ventricular systolic dysfunction, restrictive cardiomyopathy, general cardiac, cardiac deaths attributed to protocol treatment ‐ myocardial infarction and left ventricular dysfunction) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as grade 3/4 febrile neutropenia: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy (reported both sensory and motor): NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0006" title="HendersonIC , BerryDA , DemetriGD , CirrincioneCT , GoldsteinLJ , MartinoS , et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node‐positive primary breast cancer. Journal of Clinical OncologyMarch 2003;21(6):976‐83. ">CALGB 9344</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Congestive heart failure during treatment or post treatment follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosed congestive cardiac failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 febrile neutropenia: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 peripheral neuropathy: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0008" title="GoldsteinL , O'NeillA , SparanoJ , et al. E2197. Phase III AT vs. AC in the adjuvant treatment of node‐positive and high‐risk node‐negative breast cancer. Journal of Clinical Oncology2005;23(16 Suppl 7):Abstract 512. GoldsteinLJ , O'NeillA , SparanoJA , PerezEA , ShulmanLN , MartinoS , et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. Journal of Clinical Oncology2008;26(25):4092‐9. SparanoJ , O'NeilA , GrayR , PerezE , ShulmanL , MartinoS , et al. 10‐year update of E2197: phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high‐risk LN‐ breast cancer and the comparison of the prognostic utility of the 21‐gene recurrence score (RS) with clinicopathologic features. Journal of Clinical Oncology2012;30:1021. ">E2197</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 congestive heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": toxicity criteria not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy (reported both sensory and motor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher vomiting: toxicity criteria not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher fatigue: toxicity criteria not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher stomatitis: toxicity criteria not specified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0009" title="GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. European Cooperative Trial in Operable Breast Cancer (ECTO). Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and fluorouracil. Journal of Clinical Oncology2005;23(Suppl 7):513. GianniL , BaselgaJ , EiermannW , Guillem PortaV , SemiglazovV , LluchA , et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research2005;11(24):8715‐21. GianniL , BaselgaJ , EiermannW , PortaVG , SemiglazovV , LluchA , et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology2009;27(15):2474‐81. ">ECTO</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptomatic cardiac failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 neuropathy reported only: NCI CTC (no version provided)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 heart rhythm toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": NCT CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 mucositis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0011" title="JoensuuH , BonoP , KatajaV , AlankoT , KokkoR , AsolaR , et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of Clinical Oncology2009;27(34):5685‐92. JoensuuH , Kellokumpu‐LehtinenPL , BonoP , AlankoT , KatajaV , AsolaR , et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine2006;354(8):809‐20. ">FinHer</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "neutropenic fever": NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy (reported both sensory and motor): NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0012" title="MartinM . Fluorouracil plus doxorubicin and cyclophosphamide (FAC) versus FAC plus weekly paclitaxel as adjuvant treatment of node negative high risk breast cancer patients. Physician Data Query (PDQ)2005. MartinM , RuizA , Ruiz‐BorregoM , BarnadasA , GonzalesS , CalavoL , et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high‐risk, node‐negative breast cancer: results form the GEICAM/2003‐02 study. Journal of Clinical Oncology2013;31(20):2593‐9. ">GEICAM 2003‐02</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiac dysfunction, Grade 4 cardiac ischaemia, Grade 3 arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 sensory neuropathy: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 mucositis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 arrhythmia, Grade 3/4 congestive heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": protocol defined fever Grade 2 or higher with Grade 4 neutropenia requiring intravenous antibiotics, hospitalisation, or both </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 peripheral neuropathy (reported both sensory and motor): NCI CTC (version 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0014" title="MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Research and Treatment2010;123(1):149‐57. MartinM , Rodriguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Journal of the National Cancer Institute2008;100(11):805‐14. MartínM , Rodríguez‐LescureA , RuizA , AlbaE , CalvoL , Ruiz‐BorregoM , et al. Multicentre, randomized phase 3 study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC(90) versus 4 cycles of FEC(90) followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial. Breast Cancer Research and Treatment2005;94(Suppl 1):39. Rodriguez‐LescureA , MartinM , RuizA , AlbaE , CalvoM , Ruiz‐BorregoM . Multicenter, randomized phase 3 study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles of FEC vs 4 cycles of FEC followed by 8 weekly paclitaxel administrations: safety analysis of GEICAM 9906 trial. Journal of Clinical Oncology2004;22(Suppl 14):596. ">GEICAM 9906</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" grade 3/4: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 peripheral sensory neuropathy: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and vomiting: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 mucositis: NCI CTC (version 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0015" title="Participating Institutions of GOIM 9902 Trial, Italian Cooperative Group, Rome , Italy . Epirubicin and cyclophosphamide (EC) vs docetaxel followed by EC in adjuvant treatment of node positive breast cancer. A multicenter randomized phase 3 study. Journal of Clinical Oncology2001;20:1836. ViciP , BrandiM , GiottaF , FoggiP , SchittulliF , DilauroL , et al. A multicenter phase III prospective randomized trial of high‐dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node‐positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology2012;23(5):1121‐9. ">GOIM 9902</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reversible cardiotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "neutropenic fever" grade 3/4: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neurotoxicity: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 mucositis: NCI CTC (version 3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiotoxicity: WHO criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" grade 3/4: WHO criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neurological toxicity: WHO criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and vomiting: WHO criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: WHO criteria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 peripheral neuropathy: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0018" title="PolyzosA , MalamosN , BoukovinasI , AdamouA , ZirasN , KalbakisK , et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node‐positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment2010;119(1):95‐104. ">HORG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" grade 3/4: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neurotoxicity: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 asthenia: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0019" title="NCT01204437 . Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE‐II). clinicaltrials.gov/ct2/show/NCT01204437 (first received 17 September 2010). vonMinckwitzG , ConradB , ReimerT , DeckerT , EidtmannH , EiermannW , et al. A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52). Cancer2015;121(20):3639‐48. ">ICE II‐GBG 52</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 to 5 congestive heart failure and cardiac ischaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" grade 1 to 5: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 to 5 sensory neuropathy: NCI CTC version 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 to 5 vomiting: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 to 5 fatigue: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 to 5 mucositis, stomatitis, oesophagitis: NCI CTC (version 3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" grade 3/4: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy (reported both sensory and motor): NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" grade 3/4: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy (reported both sensory and motor): NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0022" title="MamounasEP , BryantJ , LemberskyB , FehrenbacherL , SedlacekSM , FisherB , et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node‐positive breast cancer: results from NSABP B‐28. Journal of Clinical Oncology2005;23(16):3686‐96. ">NSABP B‐28</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3 or higher cardiac dysfunction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0023" title="CoudertB , AsselainB , CamponeM , SpielmannM , MachielsJP , Penault‐LlorcaF , et al. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node‐positive breast cancer: the 8‐year follow‐up results of the UNICANCER‐PACS01 trial. Oncologist2012;17(7):900‐9. MarinoP , SianiC , RochéH , ProtièreC , FumoleauP , SpielmannM , et al. Cost‐effectiveness of adjuvant docetaxel for node‐positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology2010;21(7):1448‐54. RocheH , FumoleauP , SpielmannM , et al. Five years analysis of the PACS 01 Trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium. 2004. RochéH , FumoleauP , SpielmannM , CanonJL , DelozierT , SerinD , et al. Sequential adjuvant epirubicin‐based and docetaxel chemotherapy for node‐positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology2006;24(36):5664‐71. ">PACS 01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any serious adverse cardiac event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: WHO toxicity criteria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0024" title="BrainE , DebledM , EymardJ , BachelotT , ExtraJ , SerinD , et al. Final results of the RAPP‐01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high‐risk node negative and limited node positive (≤ 3) breast cancer patients. Cancer Research2009;69(2 Suppl 1):4101. BrainEG , BachelotT , SerinD , KirscherS , GraicY , EymardJ , et al. Life‐threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate‐risk breast cancer. Journal of the American Medical Asssociation2005;293(19):2367‐71. BrainEGC , BachelotT , SerinD , GraicY , EymardJC , ExtraJM , et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high‐risk node negative (pN0) and limited node positive (pN+&lt;/=3) breast cancer (BC) patients (pts): first analysis of toxicity. Journal of Clinical Oncology2004;22(Suppl 14):617. ">RAPP‐01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" defined as any Grade 3/4 neutropenia plus fever (&gt; 38 degrees) requiring antibiotics: NCI CTC (version 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 mucositis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0026" title="SakrH , HamedRH , AnterAH , YossefT . Sequential docetaxel as adjuvant chemotherapy for node‐positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Medical Oncology2013;30(1):457. ">Sakr</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 cardiac event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" Grade 3/4: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea‐vomiting: WHO toxicity criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: WHO toxicity criteria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" Grade 3/4: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea and/or vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 lethargy: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis (mucositis): NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0027" title="BiancoAR , DeMatteisA , ManzioneL , BoniC , PalazzoS , DiPalmaM , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial. Journal of Clinical Oncology2006;24:LBA520. CognettiF , DeLaurentiisM , deMatteisA , ManzioneL , BoniC , PalazzoS , et al. Sequential epirubicin‐docetaxel‐CMF as adjuvant therapy for node‐positive early stage breast cancer: updated results of the taxit216 randomized trial. Annals of Oncology2008;19(Suppl 8):viii77–viii88: 1820. ForestieriV . Docetaxel in adjuvant therapy of breast cancer: results of the TAXIT 216 multicenter phase III trial. Docetaxel in Adjuvant Therapy of Breast Cancer: Results of the TAXIT 216 Multicenter Phase III Trial. Naples, Italy: University of Naples Federico II, 2008. ">Taxit 216</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac function toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 neuropathy (reported both sensory and motor): NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 asthenia: NCI CTC (version 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0028" title="NCT00789581 . A randomized trial of Ixempra versus Taxol in adjuvant therapy of triple negative breast cancer (TITAN). clinicaltrials.gov/ct2/show/NCT00789581 (first received 13 November 2008). YardleyDA , ArrowsmithER , DanielBR , EakleJ , BrufskyA , DrosickDR , et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early‐stage triple‐negative breast cancer. Breast Cancer Research and Treatment2017;164(3):649‐58. YardleyDA , HainsworthJD , HarwinWN , GobleSA , DanielBR , AckermanMA , et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple‐negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology. 2011; Vol. 29:1103. ">TITAN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia": NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 peripheral neuropathy: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 nausea (vomiting not reported): NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 fatigue: NCI CTC (version 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0030" title="JonesS , HolmesFA , O'ShaughnessyJ , BlumJL , VukeljaSJ , MclntyreKJ , et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US oncology research trial 9735. Journal of Clinical Oncology2009;27(8):1177‐83. JonesSE , SavinM , HolmesFA , et al. Preliminary results of a prospective randomized trial of adjuvant chemotherapy for patients with stage 1‐3 operable, invasive breast cancer comparing 4 cycles of AC to 4 courses of TC. Journal of Clinical Oncology2001;20:128. JonesSE , SavinMA , HolmesFA , O'ShaughnessyJA , BlumJL , VukeljaS , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology2006;24(34):5381‐7. ">US Oncology 9735</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death due to cardiac event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported as "febrile neutropenia" Grade 3/4 : NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 vomiting: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 asthenia: NCI CTC (version 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 3/4 stomatitis: NCI CTC (version 1)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>NCI CTC: National Cancer Institute Common Toxicity Criteria<br/> NR: not reported<br/> WHO: World Health Organziation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Grouping of toxicity outcomes and description of individual study definitions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004421-tbl-0016"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Quality of life</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Instruments used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary of findings</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0001" title="GaugerK , BismarckFV , HeinrigsM , JanniW , Steinfeld , AugustinD , et al. Phase III study evaluating the role of docetaxel in the adjuvant setting of breast cancer patients with ≥ 4 involved lymph nodes: ADEBAR‐Study. Journal of Clinical Oncology2005;23(Suppl 16):908. JanniW , HarbeckN , RackB , AugustinD , JueckstockJ , WischnikA , et al. Randomised phase III trial of FEC120 vs EC‐docetaxel in patients with high‐risk node‐positive primary breast cancer: final survival analysis of the ADEBAR study. British Journal of Cancer2016;114(8):863‐71. JanniW , HarbeckN , SommerH , RackB , AugustinD , JueckstockJ , et al. Randomized phase III trial of fluorouracil/epirubicin/cyclophosphamide (FEC) versus epirubicin/cyclophosphamide/docetaxel in patients with node positive primary breast cancer: final analysis of the ADEBAR study. Author provided draft manuscript. Received on the 10th of March 2014. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel is equieffective, but less toxic than FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: the German ADEBAR phase III study. Cancer Research2009;69:604. JanniW , HarbeckN , SommerH , RackB , AugustinD , SimonW , et al. Sequential treatment with epirubicin/cyclophosphamide followed by docetaxel versus FEC120 in the adjuvant treatment of node‐positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. Journal of Clinical Oncology2012;30:1081. JanniWJ , HarbeckN , SommerH , RackB , SalmenJ , AugustinD , et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel vs. FEC120, in the adjuvant treatment of breast cancer patients with extensive lymph node involvement: final survival analysis of the German ADEBAR phase III study. Cancer Research2011;71:PD07‐01. NCT00047099 . Combination chemotherapy in treating women with breast cancer. clinicaltrials.gov/ct2/show/NCT00047099 (published 27 January 2003). SchonherrA , Aivazova‐FuchsV , AnneckeK , JuckstockJ , HeppP , AndergassenU , et al. Toxicity analysis in the ADEBAR trial: sequential anthracycline‐taxane therapy compared with FEC120 for the adjuvant treatment of high‐risk breast cancer. Breast Care2012;7(4):289‐95. SchwentnerL , HarbeckN , SingerS , EichlerM , RackB , ForstbauerH , et al. Short term quality of life with epirubicin‐fluorouracil‐cyclophosphamide (FEC) and sequential/cyclophosphamide‐docetaxel (EC‐DOC) chemotherapy in patients with primary breast cancer ‐ results from the prospective multi‐center randomized ADEBAR trial. The Breast2016;27:69‐77. ">ADEBAR</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 and the breast cancer‐specific QLQ‐BR23 at baseline, before each course of chemotherapy, and at 4 weeks, 6 weeks, and 6 months after completion of chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both treatment groups had decreased EORTC‐C30 scores for physical, role, emotional, social, and cognitive functioning from baseline to 28 days after chemotherapy. Global health scores also decreased in this time frame for both groups. Changes in symptom scores were generally similar between treatment groups with the exception of nausea/vomiting and pain scores. Nausea/vomiting was worse for the FEC120 group than for the EC‐Doc group (+9.42 above baseline vs +1.88), and pain scores were worse in the EC‐Doc group (+9.18 for EC‐Doc vs ‐1.61 for FEC120). Changes in items on the EORTC BR23 over time were quantitatively and qualitatively similar in the 2 treatment groups </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0002" title="MackeyJR , MartinM , PienkowskiT , RolskiJ , GuastallaJP , SamiA , et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node‐positive breast cancer: 10‐year follow‐up of the phase 3 randomised BCIRG 001 trial. Lancet Oncology2013;14(1):72‐80. MartinM , PienkowskiT , MackeyJ , PawlickiM , GuastallaJP , WeaverC , et al. Adjuvant docetaxel for node‐positive breast cancer. New England Journal of Medicine2005;352(22):2302‐13. ">BCIRG 001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 (version 2.0) and the breast cancer‐specific QLQ‐BR23 (version 1.0) questionnaires at baseline, before cycles 3 and 5, at 3 to 4 weeks after completion, and at 6, 12, and 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both FAC and TAC arms led to a transient and statistically significant reduction in QoL scores, which returned to baseline levels at first follow‐up visit. QoL measures were similar between groups and were similar to baseline measures at 6 months and at the end of 2 years </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0005" title="ShulmanLN , BerryDA , CirrincioneCT , BeckerH , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single‐agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0‐3 positive axillary nodes: CALGB 40101. Journal of Clinical Oncology2013;31:1007. ShulmanLN , BerryDA , CirrincioneCT , BeckerHP , PerezEA , O'ReganR , et al. Comparison of doxorubicin and cyclophosphamide versus single‐agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary notes: GALGB40101 (Alliance). Journal of Clinical Oncology2014;32(22):2311‐7. ShulmanLN , CirrincioneCT , BerryDA , BeckerHP , PerezEA , O'ReganR , et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology2012;30(33):4071‐6. ">CALGB 40101</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QoL results designed to study short‐ and long‐term toxicities on quality of life by treatment agent and duration. No further details provided </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QoL to be reported in a companion study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0007" title="CoombesRC , BlissJM , EspieM , ErdkampF , WalsJ , TresA , et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node‐positive breast cancer. Journal of Clinical Oncology2011;29(24):3247‐54. CoombesRC , BlissJM , EspieM , ErdkampF , WalsJJ , TresA , et al. DEVA: randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node‐positive postmenopausal early breast cancer (EBC) patients. Journal of Clinical Oncology2010;28:15. International Cancer Collaborative Group. A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients. Protocol only1997. ">DEVA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 and the breast cancer‐specific QLQ‐BR23 in the clinic at baseline and 9 months, 2 years, and 5 years after random assignment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in overall QoL or across any of the scales between treatments at 9 months, 2 years, or 5 years </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0010" title="NuzzoF , MorabitoA , DeMaioE , DiRellaF , GravinaA , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Critical Reviews in Oncology/Hematology2008;66(2):171‐80. PerroneF , NuzzoF , DiRellaF , GravinaA , IodiceG , LaboniaV , et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Annals of Oncology2015;26(4):675‐82. ">ELDA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 and the breast cancer‐specific QLQ BR23 at baseline, and at the end of the first, second, and third cycles of chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference reported for QoL global functioning scales and other items. However there was worsening of systemic therapy side effects, future perspective, nausea and vomiting, diarrhoea, appetite loss, and upset by hair loss and body experience with docetaxel compared to CMF at the end of 1 or more cycles </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0013" title="MartinM , LluchA , SeguiMA , AntonA , Fernandez‐ChaconC , RuizA , et al. Toxicity and health‐related quality of life in node negative breast cancer patients receiving adjuvant treatment with TAC or FAC: impact of adding prophylactic growth factors to TAC. GEICAM Study 9805. Journal of Clinical Oncology2005;23:604. MartinM , LluchA , SeguiMA , AntonA , RuizA , RamosA . Prophylactic growth factor support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node‐negative breast cancer: an interim safety analysis of the GEICAM 9805 study. Journal of Clinical Oncology2004;22:620. MartinM , SeguiMA , AntonA , RuizA , RamosM , AdroverE , et al. Adjuvant docetaxel for high‐risk, node‐negative breast cancer. New England Journal of Medicine2010;363(23):2200‐10. MartínM , LluchA , SeguíMA , RuizA , RamosM , AdroverE , et al. Toxicity and health‐related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‐fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte‐colony stimulating factor to the TAC regimen. Annals of Oncology2006;17(8):1205‐12. ">GEICAM 9805</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 and the breast cancer‐specific QLQ‐BR23 at baseline after each chemotherapy cycle and at 6, 12, and 24 months after completion of chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During chemotherapy, QoL decreased and was worse with TAC than with FAC, but this effect resolved by week 44. There were no statistically significant differences in QoL between TAC+G‐CSF and FAC after cycle 6 or during further follow‐up </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0016" title="DelMastroL , CostantiniM , DurandoA , MichelottiA , DaneseS , AitiniE , et al. Cyclophosphamide, epirubicin, and 5‐fluorouracil versus epirubicin plus paclitaxel in node‐positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest‐Mammella Intergruppo Group. Journal of Clinical Oncology2008;26(Suppl 10):516. DelMastroL , LevaggiA , MichelottiA , CavazziniG , AdamiF , ScottoT , et al. 5‐fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node‐positive early breast cancer: a phase III randomized GONO‐MIG5 trial. Breast Cancer Research and Treatment2016;155(1):117‐26. NCT02450058 . Adjuvant FEC versus EP in breast cancer (MIG5). clinicaltrials.gov/ct2/show/NCT02450058 (first received 21 May 2015). Participating Institutions to GONO‐MIG 5 study. Absence of clinically relevant cardiotoxicity in early breast cancer patients treated with the association of epirubicin plus paclitaxel: results from the Italian MIG 5 Study. Journal of Clinical Oncology2000;19:363. ">GONO MIG‐5</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial registry record indicates that QoL will be compared across treatment arms. No further details provided </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QoL information not yet reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0017" title="FountzilasG , SkarlosD , DafniU , GogasH , BriasoulisE , PectasidesD , et al. Postoperative dose‐dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer: a randomized phase 3 study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology2005;16(11):1762‐71. ">HeCOG</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 questionnaire at baseline and on completion of chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only 23% of participants (72 participants in E‐T‐CMF and 67 participants in E‐CMF) completed baseline and end of chemotherapy questionnaires. There was no difference between the 2 treatment arms at the beginning or at the end of chemotherapy. Significant increase in nausea and vomiting for both groups. Social functioning significantly decreased in the taxane‐containing arm, and emotional functioning and pain significantly improved in the control arm </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCIC‐CTGMA21 (<a href="./references#CD004421-bbs2-0020" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only2001. ">NCIC‐CTG MA21a</a>; <a href="./references#CD004421-bbs2-0021" title="BurnellM , LevineM , ChapmanJA , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Research and Treatment, San Antonio Breast Cancer Symposium. 2006:53. BurnellM , LevineMN , ChapmanJAW , BramwellV , GelmonK , WalleyB , et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose‐dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node‐positive or high‐risk node‐negative breast cancer. Journal of Clinical Oncology2010;28(1):77‐82. BurnellMJ , ShepherdL , GelmonK , BramwellV , WalleyB , VandenbergE , et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Research2012;72(Suppl 24):P1‐13‐01. ParticipatingOrganisations . Phase 3 randomized study of adjuvant cyclophosphamide, epirubucin, and fluorouracil versus cyclophosphamide, epirubicin, filgrastim (G‐CSF), and epoetin alfa followed by paclitaxel versus cyclophosphamide and doxorubicin followed by paclitaxel in premenopausal or early postmenopausal women with previously resected node positive or high‐risk node negative stage 1‐3A breast cancer. Protocol only issue 2001. ">NCIC‐CTG MA21b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients completed EORTC QLQ‐C30 and the breast cancer‐specific QLQ‐BR within 7 days before random assignment and afterwards </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QoL results will be reported in a separate article</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004421-bbs2-0029" title="BlissJM , EllisP , KilburnL , BartlettJ , BloomfieldD , CameronD , et al. Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. Cancer Research2012;72:P1‐13‐03. EllisP , Barrett‐LeeP , JohnsonL , CameronD , WardleyA , O'ReillyS , et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open‐label, phase III, randomised controlled trial. The Lancet2009;373(9676):1681‐92. HopwoodP , EllisP , Barrett‐LeeP , BlissJ , HallE , JohnsonL , et al. Impact of quality of life (QL) during chemotherapy (CT) of FEC‐T compared to FEC or E‐CMF: results from the UK NCRI Taxotere as Adjuvant Chemotherapy trial (TACT). Journal of Clinical Oncology2005;23(Suppl 16):661. ParticipatingOrganizations . Phase 3 randomized adjuvant study of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil versus FEC followed by sequential docetaxel in women with resected stage 1 or 2 breast cancer. Protocol only2002. ">UK TACT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selected centres invited participants to quality of life substudy. These patients completed EORTC QLQ‐C30, QLQ‐BR23, and Hospital Anxiety and Depression Scale (HADS) before randomisation, before fifth and after eighth cycles, and at 9, 12, 18, and 24 months post chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEC‐D was associated with worse global QoL (P = 0.001), physical (P &lt; 0.0001), role (P = 0.002), emotional functioning (P = 0.008), social functioning (P = 0.003), pain (P = 0.001), and fatigue (P = 0.006) compared to control. In contrast, there was more nausea and vomiting in the control group (P = 0.01) than in the FEC‐D group </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CMF: cyclophosphamide, methotrexate and fluorouracil<br/> E‐CMF: epirubicin‐ cyclophosphamide, methotrexate and fluorouracil<br/> EC‐Doc: epirubicin, cyclophosphamide‐docetaxel<br/> EORTC QLQ‐C30: European Organisation for Research and Treatment of Cancer (EORTC) core Quality of Life Questionnaire C30 (QLQ‐C30)<br/> QLQ‐BR23: breast cancer‐specific Quality of Life Questionnaire BR23<br/> E‐T‐CMF: epirubicin‐paclitaxel‐cyclophosphamide, methotrexate, fluorouracil<br/> FAC: fluorouracil, doxorubicin, cyclophosphamide<br/> FEC‐D: fluorouracil, epirubicin, cyclophosphamide ‐ docetaxel<br/> TAC: docetaxel, doxorubicin, cyclophosphamide </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Quality of life</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/full#CD004421-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004421-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall effect of taxanes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival ‐ all studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.83, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.83, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival: all studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.85, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.85, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Disease‐free survival: as defined in Cochrane protocol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.82, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 DFS ‐ excluding Boccardo, CALGB40101, NCIC‐CTG MA21 &amp; RAPP‐01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.82, 0.89]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall effect of taxanes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004421-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Type of taxane</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.81, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.82, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.82, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.85, 0.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Type of taxane</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004421-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Weekly or three‐weekly paclitaxel</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Weekly paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.65, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Three‐weekly paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.78, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Weekly Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.67, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Three‐weekly paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.79, 0.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Weekly or three‐weekly paclitaxel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004421-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sequential or concurrent anthracycline/taxane</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Sequential anthracycline/taxane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.81, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Concurrent anthracycline/taxane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.78, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Sequential anthracycline/taxane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.82, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Concurrent anthracycline/taxane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.83, 0.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sequential or concurrent anthracycline/taxane</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004421-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Addition or substitution of taxane</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Addition of taxane ‐ question 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.77, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Substitution of taxane ‐ question 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.74, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Addition of taxane ‐ question 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.78, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Substitution of taxane ‐ question 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.78, 0.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Addition or substitution of taxane</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004421-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Duration of chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Taxane‐containing arm longer duration than control arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13865</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.77, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Taxane‐containing arm same duration as control arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.81, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Taxane‐containing arm longer duration than control arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13865</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.77, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Taxane‐containing arm same duration as control arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.85, 0.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Duration of chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004421-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Number of cycles of taxane‐containing chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 3 cycles of taxane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.69, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 4 or more cycles of taxane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.86, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 3 cycles of taxane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.73, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 4 or more cycles of taxane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.87, 0.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Number of cycles of taxane‐containing chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004421-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Lymph node status</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Node‐positive‐only studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.78, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Node‐positive or ‐negative studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Node‐negative‐only studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.89, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Node‐positive‐only studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.80, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Node‐positive or ‐negative studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Node‐negative‐only studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Lymph node status</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004421-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Hormone receptor status</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Hormone receptor‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.70, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Hormone receptor‐negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.73, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Hormone receptor‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.85, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Hormone receptor‐negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.73, 0.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Hormone receptor status</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004421-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Publication status</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies with published efficacy paper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.84, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Studies with results from online thesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.48, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Studies with published efficacy paper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.85, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Studies with results in abstract format or in online thesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.67, 1.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Publication status</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004421-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Toxicities</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Febrile neutropenia by sequential or concurrent anthracycline/taxane <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.96, 2.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Sequential anthracycline and taxane treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.82, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Concurrent anthracycline and taxane treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.76 [3.36, 9.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Taxane replacing anthracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.02, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Febrile neutropenia by type of taxane <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.89, 2.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [1.88, 4.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.19, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Neuropathy (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.89 [3.23, 14.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Neuropathy (grade 3/4) by type of taxane <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.89 [3.23, 14.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.74 [1.33, 10.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.93 [3.59, 39.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fatigue (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.31, 2.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [1.65, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.58, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Stomatitis (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.93, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.28, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.31, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Cardiotoxicity (includes grade 3/4 and symptomatic CCF) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.56, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Total planned dose of anthracycline the same in both taxane‐ and non‐taxane‐containing arms </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.88, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Total planned dose of anthracycline reduced in the taxane‐containing arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.18, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Taxane replacing anthracycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.26, 3.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Nausea and/or vomiting (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.67, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.62, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.57, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Secondary leukaemia/myelodysplasia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.54, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.60, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.15, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Treatment‐related deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.63, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.76, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.14, 3.85]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Toxicities</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004421-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Risk of Bias</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.83, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.86, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Unclear or high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.65, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.85, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.87, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Unclear or high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.69, 0.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Risk of Bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004421.pub3/references#CD004421-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004421.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004421-note-1209">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004421-note-1208">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD004421-note-1207">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD004421-note-1205">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004421-note-1206">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004421\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004421\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004421\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004421\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004421\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004421.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004421.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004421.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004421.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004421.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726900430"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004421.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726900433"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004421.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9eec3dacf480',t:'MTc0MDcyNjkwMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 